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Abstract
Recombinant DNA technology and the ability to produce recombinant proteins
have significantly changed the world of pharmaceutical market. Recombinant DNA
technology using E. coli cells has successfully produced many therapeutic proteins. In
this study, the designed tag Ark-RUBY-tag facilitates rapid, and reproducible purification
of recombinant proteins expressed as inclusion bodies in E. coli cells. Purification of
Ark-RUBY-fused recombinant protein(s) can be obtained by using imidazole fractions.
Target protein can be easily removed from the Ark-RUBY-tag by enzymatic cleavage.
Ark-RUBY-fused recombinant proteins can be quantitatively detected using polyclonal
antibodies. Ark-RUBY-tag can be used to purify small peptides. By using Ark-RUBYtag, purified recombinant protein regains fully biologically active form. Therefore,
bioactive protein has wide range of application in drug-delivery.
Copper is crucial in many cellular functions. It is known that copper is necessary
in non-classical secretion by inducing multiprotein realize complex, but the involvement
of copper in complex formation is not clear. In this study, the role of copper in nonclassical protein secretion of IL-1α was investigated. This framework demonstrates the
role of copper to induce IL-1α dimerization under in vitro conditions. The dimerization
mechanism is mediated by the single cysteine at position 143 that gets oxidized resulting
in the formation of an inter-disulfide bond. The ratio of copper to induce IL-1α
dimerization is one to two that means one copper can induce two molecules of IL1-α. The
binding affinity of IL-1α to copper study showed that IL-1α binds to copper with Kd
value 1.9 μM, which suggests IL-1α is copper binding protein. Also, some binding
affinity experiments were conducted to elucidate whether copper is the only metal that

induce dimerization. Some metals showed good binding affinity, but no one induced
dimerization. Interestingly, corpus form showed high binding affinity, but it did not
induce dimerization. Also, the monomer and the dimer forms of IL-1α have binding
affinity to S100A13 with Kd values 1.30 μM and 1.34 μM respectively, which could be
crucial in the non-classical secretion of signal-less IL-1α.
The study also shows that Amlexanox (AMX), the anti-allergic drug, can bind to
IL-1α and chelates copper with kd 1.9 μM and 1.6 μM respectively. It also inhibits the
copper induced dimer formation of IL-1α. The mechanism that underlies dimer formation
inhibition of AMX is either because it binds close to cysteine 143 of IL-1α where copper
can bind and inhibits the induction of homodimer formation of IL-1α by masking the
thiol group of Cys134 or by chelating copper and preventing it from binding to IL-1α.
The results of AMX role in inhibiting dimer formation of IL-1α may help in designing a
drug that inhibits non-classical secretion of IL-1α.
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Chapter One
Introduction
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Classical and non-classical protein secretion
Signal peptide mediates protein secretion
Cellular growth, progress, and communication need large number of different
proteins that are synthesized in the ribosomes and transported to endoplasmic reticulum
(ER)-Golgi apparatus1. In order to response to exogenous stimuli, newly synthesized
proteins are exported by secretory system to their final destinations 2. The secretory
pathway applies specialized processes to the newly made proteins such as posttranslational modifications, protein sorting, and secretion. During protein synthesis,
protein translocation into ER membrane is an initial and critical step in protein
biosynthesis in eukaryotes3-5. ER contains chaperons that provide good environments for
nascent proteins by facilitating proteins folding and correct proteins conformation. Also,
ER works as proteins folding checkpoint that eliminates unfolded proteins before
delivering to Golgi machine6, 7. Protein trafficking has been an area of discussion for a
long time since Blobel and colleagues pioneered the basis of proteins translocation across
intracellular membranes8.Reaching the right targets, newly made proteins need to be
carried to protein sorting in the ER-Golgi system. In biological system of eukaryotic
cells, signal peptide mediates proteins translocation across the membrane like system of
ER that composes the secretory machine of living cells. Passing the ER existing sites,
proteins are packed into membranous vesicles. After vesicles carrying proteins are
delivered to Golgi apparatus, post Golgi apparatus cargos undergo fusion with the plasma
membrane that results in the release of conventional secretory proteins into extracellular
chamber. Each delivered protein requires a valid cellular address tag to govern protein
export from the synthesis site to functional sites9. However, many aspects of protein
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transporting processes were not clear. Synthesized proteins contain specific amino acid
sequences that is called signal segment guiding the protein to the final destination9, 10.
Intracellular compartments are delivered right proteins based on the signal segment.
Signal segments are either a linear sequence of amino acids or a given residues forming
up for interaction in the correct three-dimensional conformation of the cargo protein10.
Each organelle is received a specific protein based on the interaction between the
different receptors on their surface with a specific signal sequence, thus the information
that are encoded in the signal sequence directs the specificity of targeting (Figure 1).
Once a protein/receptor interaction has occurred, some kinds of translocation channels
are opened. In mammalian cells, specific channels are called translocons that translocate
newly synthesized proteins into final destination11, 12. Sometimes, for some proteins, it
needs to reach a sub compartment within the target organelle4, 13. Lastly, once the
translocation across the membrane is complete, a specific protease removes the signal
sequence from the mature protein14, 15.
Signal-less proteins and Non-classical pathways
In classical protein secretion, proteins containing N-terminal signal peptide
translocate into the lumen of ER, which is followed by ER/Golgi dependent transport to
the cell surface for example, albumin, fibrinogen, and immunoglobulin8. However, signal
peptide is not presented in many primary structure of different proteins and yet they exert
their actions by binding to specific surface receptor16, 17. Moreover, signal-less peptide
secreted proteins play a key role in many physiological processes such as inflammation,
angiogenesis, and cell growth and differentiation18. Some secretory proteins are known
for extracellular functions, but they do not have signal peptides and ER does not mediate
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their membrane transportation into extracellular space19.These proteins are found to be
involved in diseases. Examples of these proteins are interleukin-1 α, interleukin-1β,
galectin 1 and 3, β galactoside specific lectins, fibroblast growth factor 1 and 2, infection
related cell surface markers of Leishmania parasites (HASP family), and viral proteins
such as Herpes simplex tegument proteins vp22 and HIV-TAT proteins etc. Interestingly,
these proteins have non-endoplasmic localization or Golgi apparatus localization, with no
ER/Golgi post translation modification such as glycosylation and most importantly their
release cannot be interfered by protein secretion inhibitors such as berfeldin A, which is
the classical proteins secretion inhibitor20. These findings bring a new term in proteins
secretory mechanism that assures fully cellular functions in absence of signal peptides.
Therefore, proteins secretion that mediates out of ER/Golgi system is called nonclassical/unconventional protein secretion process21, 22. Unconventional secretory
pathway involves four mechanisms (Figure 1), two of which include intracellular vesicles
of endocytic system such as secretory lysosomes and exosomes and the third export
mediates plasma membrane-resident transport and the last one involves the plasma
membrane shedding of micro-vesicles23, 24. FGF2 export is mediated through the cell
membrane. Pores formation helps in moving leaderless proteins through without breaking
the membrane. During stress, membrane pores construction needs fully folded leaderless
proteins that accumulate near and interact with phosphatidylinositol 4,5-bisphosphate
(P1P2) of cytoplasmic side of the membrane. The interactions induce conformational
changes of P1P2 that triggers pores formation. Once the pores are made, leaderless
proteins can easily translocate to the extracellular space. Even though pores formation
explains how the membrane is kept intact, it does not elucidate how proteins that do not
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interact with P1P2 can induce oligomerization to make pores. FGF1 and FGF2 are
prototypic members of FGFs family and they share some structural properties, but FGF1
secretion requires another signal-less protein to form multiprotein complex that includes
S10A13, sphingosine kinase, synaptotagmin, and annexin 2. Then, with the help of
annexin 2, the membrane is flipped outside to release the protein complex. Some
cytoplasmic proteins are secreted during inflammation by either cell lysis or changing in
cell membrane permeabilization. Cell lysis occurs during the inflammation while some
immune cells work to destroy irritant action. Best example for lysis protein secretion is
IL-1 β. However, some researchers have shown that IL-1 β is secreted without destroying
the cells. It is secreted when cells permeability changes after gasdermin-N, a result of
caspase 1 catalyzed gasdermin cleavage, is inserted in the cell membrane. However, IL-1
α secretion needs to interact with S100A13 to be exported outside the cells.
Non-classical protein secretion of IL-1α
The most common form of IL-1α found in cells is the precursor protein25, 26.
Precursor IL-1α (proIL-1α) can generate the IL-1R1 signaling once it is released. ProIL1α is processed by the Ca2+ dependent protease calpain to form mature form of IL-1α 27,
25,26.

IL-1α export requires Cu2+ and its binding protein S100A13. IL-1α-S100A13

complex is in a Cu2+ dependent manner and the complex formation is released from the
cells when the cells are exposed to heat stress16, 28. Interestingly, precursor IL-1α is active
by its own and the necessity of cleavage is not clear. The latest study suggested that
cleavage process might increase its potency29. Several proteases play role in precursor IL1α cleavage include, neutrophil elastase, NK-granzyme-B, mast cell chymase, and
calpain proteolysis30.
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Figure 1: Demonstrates different mechanisms of proteins transport (export) systems.

It is well known that products of cleavage of enzymatic proteolysis are more
potent than the precursor protein in activating cells. During NK-mediated killing of target
cells, granzyme-B cleavage of proIL-1α occurs. ProIL-1α can be cleaved to enhanced
inflammatory response of inflammatory cells. Cleavage of the precursor takes away the
carboxyl-terminal mature part of the molecule where the NLS which is the nuclear
translocation and DNA binding part of the protein31. Therefore, the mature form of IL-1α
produces from cleavage process, cannot be retained in the nucleus leading to its release
from the cell with great affinity to the receptor. Caspase-1 was recognized to have a role
in processing and secretion of IL-1β. It is secreted in combination with IL-1β from
specialized secretory lysosomes. In regard to IL-1α, Caspase-1 might assist the secretion
of IL-1α32. Several studies on Caspase-1 knockout mice shown a reduction in the
secretion of both IL-1 α and IL-1β33-80. At intracellular level, a binding protein, called
interleukin-1 receptor 2 (IL-1R2), protects IL-1α precursor. Certainly, IL-1R2 binding to
precursor IL-1α inhibits its cleavage and release from necrotic cells. It is suggested that
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caspase-1 helps removing IL-1R2 from precursor IL-1α that ultimately leads to cleavage
and secretion of IL-1α. Several players are affecting the inflammatory potential
including, the levels of IL-1 α, calpain, the extent of necrosis and the expression of
intracellular IL-1R2, and its cleavage by caspase-1 and intracellular levels of Ca2+26, 34, 35.
Copper and Unconventional protein secretion mechanism
In non-classical protein secretion of FGF1, copper is required in order to form
multi proteins complex of FGF1, P40, S100A13 and Syt1. Kumar group has
demonstrated that copper stimulates FGF1 dimers as well as S100A13 dimers in the
stressed release of FGF136. Many proteins have been linked to FGF1 secretion during
stress. Sphingosine kinase 1 (SK1), a copper-binding protein, mediates sphingosine-1phosphate formation, lacks the signal peptide sequence, and is also secreted by nonclassical protein secretion. In presence of copper, FGF1 is found to make high molecular
weight complex with SK137. Prudovsky group has showed that SK1 has high affinity to
copper that makes the protein to be copper donor in stress release of FGF1. Treating the
cells with copper chelating agent called tetrathiomolybdate (TM) blocks the effects of
copper induce dimerization leading to decrease cancer growth. However, large expression
of SK1 seemed to rescue FGF1 release in present of TM. Many studies have shown that
proteins binding to different metals have various effects38. For example, S100A13 binds
to calcium as well as copper, but each ion has diverse binding matters. It is very
interesting that the bindings sites of those two ions are located close to each other on the
S100A13. Moreover, thermodynamic stability of S100A13 dimers totally depends on
these ions in a way that this protein structure usually destabilized significantly when it
binds to copper whereas binding to calcium structure is more stabilized. Copper not only
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stimulates protein conformational changes but also it helps in cellular communications.
Even though IL-1α, IL-1β, FGF1, and FGF2 have low amino acids homology, they share
unique biological aspects. They all have no signal peptide, secreted by unconventional
protein secretion, and they all compose twelve β-sheets. More interesting, some of them
share the secretion pathway. For example, IL-1α and FGF1 export is similar in
responding to cellular stress39. In addition, some complex structure formation upon stress
exposure follows similar traits in both proteins. This is noted in the release complex
formation that includes S100A13 and Cu2+-dependence, which is stress-dependent40. As
SK1 is a copper provider for stress secretion of FGF1, it may work for IL-1α (Figure 2).

Figure 2: Elucidates the proposed mechanism of copper induces IL-1 α secretion by nonclassical secretin16.
However, IL1α export does not require p40 Syt1 compared to FGF1export.
Kumar group has proposed that, it might indicate another unknown cytosolic protein is
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playing this role instead of p40 Syt1 in the IL1α release complex. The p40 Syt1 protein is
involved in other proteins stress-induced export like syntaxin 2 (epimorphin) in addition
to annexin II. The export of IL1β and FGF2 might require S100A13, p40 Syt1, SK1,
annexin II, and Cu2+ but this assumption need to be further clarified. Cu2+ might be
involved in the association of the members of multiprotein aggregates involving FGF1,
IL-1α, S100A13 and p40 Syt1 that are all Cu2+-binding proteins. Cu2+ induces FGF1
homodimer but not FGF2 even though two of the three cysteine residues present in FGF1
are conserved in FGF216. In addition, Cu2+ might participate in the non-classical release
of angiogenic and pro-inflammatory polypeptides as many studies have demonstrated
angiogenic and pro-inflammatory effects of Cu2+. It has been noted that attenuation of the
stress-induced release of IL-1α and FGF1, as well as of S100A13 when co-expressed
with IL-1α or FGF1 is achievable via the depletion of intracellular free Cu2+ through
continuous application of a specific chelate, tetrathiomolybdate (TM). Therefore, the
stress-induced Cu2+-dependent assembly of IL-1α and FGF1 multiprotein release
complexes is indeed a requirement for the non-classical export of these proteins in vitro
as demonstrated by different studies41, 42.
Cell Signaling and Growth Factors
In multicellular organisms, cellular communication between millions of cells is
critical function for allowing different cells work together. Cellular responds to
environmental changes are essential for regulating biological pathways. Cellular
commination can be taken place by sending different molecules including proteins, lipid,
gas, and polypeptide43. The process of cell signaling is either by passing molecules
between two adjacent cells through the gap junctions or by releasing growth factors 44, 45.
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Cellular response occurs when a cell recognizes a signal that comes from either the
environment or produced by another cell, via a receptor; then receptor-ligand complex
generates signal transductions46. In multicellular organisms, the growth factors are
important cell signaling molecules because growth factors provide different cell-to-cell
communication mechanisms including endocrine signaling (long distance interaction),
paracrine signaling (nearby interaction), and autocrine signaling (self-interaction).
Growth factors carry information to trigger gene expression, cellular differentiation, and
mitogenesis47. They help promoting cellular growth and cellular productions in response
to many environmental changes. Growth factors are usually small proteins known as
cytokines48. Cytokines are secreted proteins that have specific roles on cellular
interactions and communications.
Based on the type of secreting cells, there are many kinds of cytokines including
lymphokines (secreted by lymphocytes), monokines (secreted by monocytes), and
interleukins (secreted by leukocytes and interact with leukocytes). Interleukins are a set
of proteins that thought to be particularly secreted by the leukocytes. Interleukins play
important functions in cellular communication, cellular growth, and immune responses.
They are categorized into various families based on the homology of their amino acids
sequences, targeting specific receptors, and performing similar functions49. Interleukin-1
family (IL-1) was the first group of interleukins that was identified50. IL-1 family is a
pro-inflammatory cytokine with several effects on cellular proliferation, differentiation
and immune reactions. Nine members are under the name of IL-1 family51. Among many
other cytokines, IL-1 family of cytokines is primarily mediated with inflammatory
response against several harm irritations52.
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Figure 3: Interleukin 1 family members tree.
Even though members of IL-1 family of cytokines are associated with innate immunity
response, many inflammatory disease such as degenerative diseases are linked to
uncontrolled secretion of some interleukin-1 family members53.
Interleukin 1 alpha (IL-1α)
In 1974, two different isoelectric forms of IL-1 with two different molecular
weights were reported by Dinarello54. An acidic human form with molecular weight of
31,000 Da corresponding to IL-1α and another neutral human form corresponded to
human IL-1β with a molecular weight of 17,000 Da. Interleukin-1α (IL-1α), is one of the
molecules that have been recognized long time ago; still a lot of data about its role in
various diseases are vague. The term of interleukin has roots started in the early 1940s,
when sterile pus was injected into rabbits causing a fever55. Many years later, a group of
researchers conducted an in vivo study on white blood cells investigating the causative
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agent(s) that induced the fever56. At that time, they found a molecule acted as a
thymocyte mitogen, so the term endogenous pyrogen was used (EP)57. Later, in the
second international lymphokine workshop that held in Interlaken, Switzerland, the term
interleukin came up in honor of the city where the meeting was conducted58. IL-1α is one
of the leaderless proteins that lack a signal peptide. This means its secretion is aimed
without endoplasmic/Golgi system59. IL-1α is an exceptional type of cytokine as it
always presents inside all resting non-hematopoietic cells as well as hematopoietic cells
in both healthy and unhealthy situations60. In addition, it is usually up regulated during
hypoxic situations. Moreover, it has a vital role in necrosis that mediates early
inflammatory reactions triggered by its release from damaged tissues 61. It acts through
recruitment of neutrophils to the damage site, besides its induction by different released
cytokines and chemokine from inflammatory cells in the surrounding tissue. It has a
unique role in multiple inflammatory diseases. Moreover, IL-1α plays key roles in many
cellular processes such as cellular proliferation, angiogenesis, and tumor growth. IL-1α is
known to act as transcription factor inside the nucleus to induce cells to make many
mRNA expressions of other cytokines such as IL-6 and IL-8 and itself as positive
feedback control (Figure 2). Also, it acts as secreted protein outside the cells binding to
specific receptors62. Furthermore, some studies showed that IL-1α is expressed as
membrane bounded protein works as cancer cells surveillance62. IL-1α can increase
immunogenicity against tumor cells and serve as anti-tumor immune. Upon membrane
bound form, IL-1α can be glycosylated and placed on the cell membrane of activated
cells like monocytes or macrophages, and other cells, by a lectin-like association to
induce inflammation63, 64. This membrane-associated IL-1α activates IL-1R1 on target
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cells, such as endothelial cells and T-cells, and in fibroblasts. Membrane-associated IL1α has been recognized as main cytokine that potentiates stimulation of other cytokines in
the senescence-associated secretory phenotype (SASP) response. This response involves
secretion of pro-inflammatory cytokines, such as IL-6 and IL-865. On the other side, when
a tumor cell reaches senescent, the resulting inflammatory response can promote
invasiveness66-67. Also, when cancer cell dies, precursor IL-1α is released acting as
inflammatory inducer that may lead to tumor invasiveness and angiogenesis 62, 68.
Interleukin-1  expression
Interleukin-1 is expressed in many different cells at steady state in both healthy and
non-healthy condition, but its secretion level is increased in response to stressed
conditions. In contrast to other interleukins, IL-1 can be generated by endothelial cells
as well as epithelia cells57, 69, 70.
Interestingly, IL-1 gene contains a binding site for Sp1 transcription factor that
is known to regulate housekeeping genes instead of canonical TATA and CAAT
regulatory regions71. IL-1 expression varies based on the type of the cells. For example
in monocytes, the regulation involves the long noncoding RNA-AS IL-1 transcription
factor that is partially complementary to IL-1 mRNA72. However, in human CD4+ T
cells, the hypo/hyper methylation of CpG nucleotides in the transcription initiation site
regulates IL-1 gene expression73. The IL-1α gene is located on the long arm of
chromosome 2 end to end to the IL-1β gene74. The first IL-1 cDNA was cloned in 1984
from two different species, human blood monocyte and a mouse cell line75, 76. The IL-1
gene product in those sources was different as the human product was neutral and the
other was acidic54. The IL-1 α gene primary product is a 271 amino acid precursor then it
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is processed to produce a shorter mature protein, which is the carboxyl terminal end of
the precursor27.
Interleukin 1 alpha structure
After removing the pro-piece mature form of interleukin 1 alpha is 162 amino
acids protein with 18.5 KDa. It is entirely made of twelve antiparallel β-sheets. In the
center, six-stranded β-barrels are arranged to be closed to another six β-strands forming a
bowl like structure. At the N-terminus, a short β-strand that composes 6-18 then another
short β-strands of amino acids 97-99. Amino acids 101-105 make two turns. Three-fold
structural symmetry in the protein core.

Figure 4: shows the three-dimensional structure of interleukin 1 alpha. Twelve anti
parallel beta strands that make the bowl shape at the center of protein core16.
IL-1α receptors
IL-1α, IL-1β and IL-1Ra exhibit the biological functions by specific binding to
IL-1R177, 78. Various human cells such as T-cells and fibroblasts express the 80 KDa IL1R1. The extracellular domain of IL-1R1 composes of 319 amino acids assembled in
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three Ig-like domains79. Also, the cytoplasmic domain that has strong homology to toll
like receptor comprises of 215 amino acids80. IL-1α can bind to IL-1R2 with no effects.
Interestingly, IL-1R2 is 60 KD and it is shorter than IL-1R181. This observation explains
that IL-1R1 and IL-1R2 are produced from different genes. It is believed that IL-1R2
works as decoy to control and regulate the biological functions of IL-1α and IL-1β82. The
extracellular domain of IL-1R2 also consists of three immunoglobulin domains. IL-1R2
contains a short intracellular cytoplasmic tail that is 29 amino acids long. This indicates
that two IL-1 receptors interact with different signal transduction pathways 83. IL-1R2 is
expressed by a number of cells including B and T-lymphocytes. Upon exerting the
biological roles, IL-1α binds with high affinity to the IL-1RAcP making tetramer protein
complex with IL-1R181. The binding reaction requires firstly IL-1α causes
conformational changes to IL-1R1 upon binding then secondly the conformational
changes in the IL-1R1 allow IL1-RAcP to bind to the IL-1/IL-1R1 complex leading to
signal transduction. IL1-RAcP provides high stability signals that increase IL-1 binding
affinity84.
IL-1 α signaling
IL-1 α signaling is activated in response to infection, tissue injury or stress 85.
Mitogen-activated protein (MAP) kinase p38, extracellular signal-regulated kinase 1/2
(ERK1/2), c-Jun N-terminal kinase and nuclear transcription factor κB (NFκB) are the
main pathways that are activated by IL-1 α86, 87. The hetero-tetramer complex of IL1RAcP and IL-1R1 /IL-1α complex is required for increasing binding affinity and to
introduce the signal transduction. The cytoplasmic domains of IL1-RI and IL1-RAcP
belong to the Toll like receptor (TLR) family reported as Toll/interleukin-IL-1 (TIR). The
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creation of the IL-1/IL-1RI /IL1-RAcP complex enables recruitment of the adapter
molecule MyD88, which also contains TIR domain, to the TIR domains of IL1-RI and
IL1-RAcP81. Binding of IL-1 with the IL1-RII decoy receptor leads to loss of the TIR
domain, which is required for signal transduction. Subsequently, the serine/threonine of
IL-1 Receptor Associated Kinase IRAK-1, IRAK-2 and the IRAK-4 are recruited and
activated by MyD88. In a resting state, IRAK-1 is associated with a Toll-interacting
protein (Tollip)87. The phosphorylation of Tollip is required for IRAK-1 activation. These
multiple kinases cause the recruitment and activation of tumor necrosis receptorassociated factor-6 (TRAF6)88. The IRAK-1/TRAF6 complex interacts with transforming
growth factor β-activated kinase-1 (TAK-1) within the cytoplasm, which then
phosphorylates the IκB kinase (IKK) complex. The degradation of the phosphorylated
IKK is leading to translocate NFκB to the nucleus and activate gene expression89.
Alternatively, the interaction between TRAF6 and the TRAF associated protein named
evolutionarily conserved signaling intermediate in Toll pathways (ECSI), causes
activation of c-Jun through the Map kinase/JNK signaling cascade90.
Role of IL-1 α in pathogenesis of various diseases
Role of IL-1α in inflammation and autoimmune diseases
IL-1α is associated with various scopes of many diseases and causes a sterile
inflammatory response. Also, there are increased levels of IL-1α in synovial fluid of
rheumatoid arthritis patients91, 92. In psoriasis, IL-1α amplified level is found to correlate
positively with disease severity and keratinocytes express IL-1α constitutively93. The
presence of IL-1α in resting cells constantly can explain why IL-1α has emerged as a key
cytokine in eliciting sterile inflammation. Toll like receptor helps to distinguish between
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self and non-self-molecules by binding to pathogen associated molecular pattern
(PAMPs)94. On the other hand, tissue injury requires identifying alarm signals to approve
a sterile environment. In this case, alarm signal is precursor IL-1α that activates
inflammatory responses against dead cells95, 96. On the contrary, in cells directed to the
apoptotic pathway, IL-1α stays inside the nucleus, and fails to initiate an inflammatory
response97, 98. This retention of IL-1α ensures by binding chromatin to nuclear IL-1 α89, 97.
This linkage is tight, that reduce the mobility of IL-1α preventing its release97, 99.
Additional significant study showed that IL-1 α released from dead cells lead to
activation of IL-1R1100. In experimental models to study peritonitis in mice, an
inflammatory response and neutrophil infiltration occurred in an IL-1 α dependent
manner by the injection of cell lysate in the peritoneal cavity101. It is believed that IL-1α
was mainly released from necrotic cells and the surrounding mesothelial cells secrete CX-C motif chemokine ligand 1 (CXCL1) through an IL-1R1-Myd88 signaling dependent
manner102.
Correlation of IL-1α with neurodegenerative diseases
Furutani et al. in 1986 had paved the way to new discovery in the field of
inflammatory diseases when the sequence and the organization of the IL1α gene was
published103. For instance, in systemic sclerosis (SSc), which is a known inflammatory
disease, IL-1α is up regulated in fibroblast cells. This up regulation triggers an
inflammatory process involving IL-6 and procollagen leads to worsening the autoinflammation and fibrosis associated104, 105. Fibroblast cells obtained from SSc biopsies
showed an increased level of transcription of IL-1α106. This activated IL-1α increases
inflammation107. Alzheimer’s disease (AD) is one of the neurodegenerative diseases, in
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which an inflammatory process causes loss of neurons. Biopsies on postmortem human
brain tissue sections from AD patients exhibited an elevated levels of IL-1α in the
temporal lobe108. A characteristic finding in all AD biopsies is the presence of Betaamyloid plaques that correlates with IL-1 α expression in microglia cells109, 110, 111, 112, 113.
IL-1α genetic variation was found to play a role in the occurrence of periodontal disease,
an inflammatory disease, which is associated with bacterial plaque due to poor oral
hygiene, but is also common among smokers and diabetic patients 114, 115. In non-smokers,
the disease noticed to be associated with elevated IL-1α protein levels and the T allele at
the −889 position116, 117.
IL-1α role in tumor
There are a lot of pro-inflammatory cytokines that contribute to the process of
carcinogenesis118, 119. The role of IL-1 in tumor progression and invasiveness has been
extensively a focus of many researchers. Mutually IL-1 agonistic molecules (IL-1α and
IL-1β) can promote tumor invasiveness, metastasis and chemical-induced carcinogenesis
through inflammatory responses they induce if they are present in their secreted form. A
lot of data clarified the fundamental role that IL-1 molecules play in the development of
tumor-induced angiogenesis120, 121. Such as, IL-1α and recombinant IL-1β are well-known
angiogenic promoting factor. Though, the effects of micro-environmental IL-1α on
melanoma development in mice were significantly less than the effects of microenvironmental IL-1β.
Chronic inflammation has been linked with malignant transformations 122, 123.
Many studies have observed that secretory form of IL-1α is a well-recognized pro
inflammatory cytokine in tumor microenvironment that fasten tumor growth and
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invasiveness, whereas membranous form of IL-1α when present in tumor cells lead to
trigger destruction of this cell by immune-mediated mechanisms124, 125. Early infiltration
by macrophages and CD8+ T cells lead to regression in tumors expressing IL-1 α in vitro.
On the contrary, in vivo absence of CD8+ T cells but not CD4+ T cell abolishes
regression of IL-1α- positive fibrosarcoma tumors. Long-term specific immune memory
protects mice against a challenge with wild type cells (IL-1α-negative). The mechanism
by which IL-1α expressing tumor cells cleared by the immune system has been a focus of
a lot of researchers. Recently, it has been hypothesized that membrane-associated IL-1 α,
may possibly serve as a second co-stimulatory signal or focused adjuvant for their direct
activation when ligates to IL-1R1 on effector cells, such as CTLs. Additional, antigen
presentation by the tumor cells themselves can be triggered by tumor cell-associated IL1α through IFNα- induced MHC class II expression, or via cross-presentation by
professional APCs. The eradication of IL-1α-positive fibrosarcomas might be through
non-adaptive effector cells, such as NK cells and activated macrophages. Membraneassociated IL-1α immunotherapeutic effects were tested as anti-tumor in tumor-bearing
mice. Therefore, Mitomycin-C-treated IL-1α expressing cells that introduced at the
critical “therapeutic window” caused regression of wild type fibrosarcoma cells 124.
Similarly, regression of invasiveness of malignant lymphoma was shown if cellassociated IL-1α was expressed. Also, invasive T lymphoma cells, which metastasize to
the spine showed regression if transient cell-associated IL-1α was expressed126. This
shows that a difference present between cell-associated IL-1α and secreted IL-1α. In case
of pancreatic adenocarcinoma, tumor-associated IL-1α was found to be the triggering
factor of tumor growth. The binding of IL-1α to its receptor on cancer-associated
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fibroblasts stimulates the production of inflammatory factors. For example, neutralization
of IL-1α signaling was used to reduce these inflammatory effects. Extracellular IL-1α
that was released from dying cells caused these effects 127. IL-1α seems to be expressed in
different varieties of tumors. It acts with IL-1β and MyD88 to increase reactive oxygen
and nitrogen species, COX-2, phosphorylated NF-kB inhibitor (IkB) and stress-activated
protein kinase/c-jun-NH(2)-kinase, inducing promotion of tumor progression128.
Undoubtedly, IL-1 α behaves in different ways in tumor cells depending on whether it is
secreted or being intracellular. Secreted form IL-1α might induce inflammation and
favor tumor progression, as does IL-1β. Intracellular form, IL-1α is displayed on the
membrane and induces anti-tumor cell immunity that might limit growth and regression.
Certainly, IL-1α deficient mice displayed a delay in tumor growth and an impaired
angiogenic response. Additionally, the role of IL-1α in pancreatic cancer progression
might be through promoting angiogenesis and in prostate cancer it might be due to upregulation of immunosuppression of cytokines in mesenchymal stem cells 129, 130.
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Abstract
The efficiency of protein purification is vital to the development of
pharmaceuticals and to the evolution of biomedical research. The cost of the most
common techniques used for purification of recombinant proteins constitutes a significant
portion of the multi-billion-dollar pharmaceutical industry, particularly due to the
conversion of some proteins into inclusion bodies when using a heterologous host.
The investigations into more cost-effective and less labor-intensive methods for
the purification of recombinant proteins are important to receive higher yields at a
lowered monetary investment. Rubredoxin (Rd) is a 53 amino acid long protein, which is
an ideal tag due to its low molecular weight (7kDa), red color for easy identification, and
extreme thermostability. The Rd protein is the tag used in the purification of IL-1α, D2
(FGF1 receptor domain), and the anti-fungal peptide. This novel tag has been named
ARK-RUBY-tag which stands for Arkansas Rubredoxin purification tag and ruby refers
to the red color of the protein. The tag was able to keep all recombinant proteins in
soluble form. The protein expression was monitored by the presence of the red color.
Since the main subject of this project is IL-1α, the tag and the fusion protein were
examined thoroughly, which shed light on the main properties and characterization of the
tag. Utilizing the tag, IL-1α was purified in high yields and displayed good bioactivity.
The Ark-RUBY- recombinant proteins showed significant thermal stability.
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Introduction
Recombinant DNA technology and the production of recombinant proteins have
evolved in the pharmaceutical and biotechnological industry through the introduction of
drug-based protein production for use in healthcare1. Due to unsatisfactory yields of
bioactive proteins isolated from their natural sources, the large-scale production of
recombinant proteins in suitable heterologous host systems have been of significant
interest2, 3. In particular, Escherichia coli (E. coli) has been extensively used as a suitable
heterologous host to facilitate recombinant protein expression because it is compatible
with various cloning vectors, its amenability to genetic modification(s), high
transformation efficiency, and its adaptability for rapid high-density cultivation under
variety conditions4-6. However, high yield of recombinant protein expression in E. coli
causes protein aggregation and inclusion bodies (IBs) formation, which is a common
major problem in the large-scale production of recombinant proteins in heterologous host
systems7, 8. IBs are dense intracellular bodies mostly consisting of aggregated
recombinant proteins that are misfolded and hence are functionally inactive9. Recovering
of target recombinant proteins which form inclusion bodies involves multiple steps such
as, isolation of pure inclusion bodies, solubilization of inclusion bodies, refolding of
solubilized recombinant protein(s) and purification of refolded proteins using different
various chromatographic techniques10-12. Inclusion bodies are highly specific aggregates
and mostly consist of the recombinant protein of interest13, 14. Owing to the multiple steps
involved, the yields of the pure and bioactive target recombinant proteins from IBs is
often very low15, 16. Biotechnology and pharmaceutical companies incur huge losses
amounting to millions of dollars in lieu of the multiple, cumbersome, time-consuming,
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and labour-intensive steps involved in recovery of recombinant proteins that are
biomedically significant or serve as potential therapeutics against a wide array of
diseases5, 17. In this context, there is immense commercial interest in designing methods
to thwart the overexpression of recombinant proteins, of biomedical importance, as
inclusion bodies. The target fusion protein is overexpressed and the specific binding
characteristics of the affinity tag are exploited to selectively purify target fusion proteins
by employing a relevant affinity chromatographic technique18, 19. The affinity tag is
subsequently separated from the target protein by selective cleavage of the target fusion
protein using restriction proteases20. A number of fusion protein tags including,
glutathione S-transferase (GST)21, thioredoxin A (TrxA)22, maltose-binding protein
(MBP)23, poly histidine (His)24, green fluorescent protein (GFP)25, streptavidin,
ketosteroid isomerase (KSI)26, and heparin binding (HB)27 peptide have been successfully
used for the overexpression and purification of recombinant proteins in different
expression hosts including E. coli. However, use of these purification tags has one or
more significant limitations such as, i) higher molecular weight of affinity tags which
reduces column capacity28, ii) poor solubility of affinity tag(s)24, iii) high costs of affinity
resins29, iv) low expression yields30, v) interference with the folding and functional
properties of target recombinant proteins, vi) involvement of expensive mobile phase
buffers28, and vii) poor temperature stability and susceptibility to proteases secreted by
expression hosts31. In this context, there is significant interest toward the development of
a protein affinity tag that renders recombinant protein overexpression and purification
simple, efficient, versatile, and cost-effective32, 33.
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Rubredoxin (Rd) is a small molecular weight monomeric non-heme iron-sulfur
protein (7 kDa), composed of 53-58 amino acids34, 35. Rd has been isolated from several
thermophilic and mesophilic organisms36. Rd was first identified from Pyrococcus
furiosus (PfRd), a hyperthermophilic anaerobic archaeon able to thrive in oceanic hot
springs at temperatures approaching 100°C37, 38. Rd protein has an exceptionally high
thermal stability (Tm > 90°C)36. Rd from Pyrococcus furiosus is the most stable protein
which has currently been identified39. Rd belongs to the α and β class of proteins
consisting of 2 α-helices and 2 or 3 antiparallel β-strands40. The active site of Rubredoxin
contains an iron-sulfur cluster [Fe2S2] wherein an iron ion is coordinated by the sulfurs of
four cysteine residues of the protein40. The expression of recombinant proteins in E. coli
was monitored using the absorption of Rd from Thermotoga maritima at 380 nm41.
Overexpression and purification of recombinant proteins were achieved using rubredoxin
from a mesophilic anaerobic bacteria, Desulfovibrio vulgaris42. However, using this
technique was limited by the difficulty to prevent the formation of inclusion bodies due to
the lower thermal stability and slower folding rates of this bacterial strain. Moreover,
there was loss of the iron sulfur center, responsible for the red color formation, due to the
lower stability of the rubredoxin from Desulfovibrio vulgaris during large-scale
production of recombinant proteins41. Interestingly, Rubredoxin from Pyrococcus
furiosus shares about 63 % amino acid sequence identity with its mesophilic
counterpart43, 44. In this context, in the present study, a novel polyhistidine Rd purification
tag was designed, which I would prefer to hitherto name as Ark-RUBY (Arkansas
Rubredoxin purification tag), for the soluble overexpression of recombinant
protein/peptides in heterologous hosts. Linking the polyhistidine tag to Rd is also
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expected to aid in the purification of Ark-RUBY fused target protein/peptide(s) using
nickel/cobalt affinity chromatography45-47. Also, the amino acid sequence of Rd does not
contain methionine. This aspect will facilitate the cleavage of the Rd-fused methionineless recombinant protein/peptide(s) in a cost-effective manner using cyanogen bromide
(CNBr), a reagent that specifically cleaves polypeptide chains at the C-terminal end of
methionine48-50.
Experimental methods
pUARC-RUBY expression vector and construction and expression of the ArkRUBY-IL-1α, Ark-RUBY-D2 and Ark-RUBY-AF gene
The designed expression vector with novel peptide fusion partner to Rd
(Rubredoxin, little iron-Sulfur protein: originated in P. furiosus) for E. coli heterologous
expression is outlined (Figure 1).

Figure 1: Map of pUARC-RUBY plasmid: The rubredoxin gene with 9-histidine tag
cloned under tac promoter. The carboxyl terminus of RD gene sequence encodes specific
thrombin site with overlapping BamHI and other MCS in pGEX series vector. The
segment map of promoter, rbs, RD and MCS are highlighted below. The total sequence
of pUARC-RUBY is 4500bp.
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As depicted in illustration, the higher copy number origin, Ori is with tac promoter, as
highly successfully used for GST tagged pGEX series vectors. The Rd gene sequence (5'ATGGCGAAATGGGTGTGCAAAATTTGCGGCTATATTTATGATGAAGATGCGG
GCGATCCGGATAACGGCATTAGCCCGGGCACCAAATTTGAAGAACTGCCGGA
TGATTGGGTGTGCCCGATTTGCGGCGCGCCGAAAAGCGAATTTGAAAAACTG
GAAGAT-3’) was used with unique 9-histidine tag encoded by
(5’CATCATCACCATCACCATCACCATCAC3’) the fusion partner at the amino
terminus. The specific thrombin cleavage site of LVPRGS encoded by
(5’CTGGTGCCGCGTGGATCC-3’) was used as part of multi-cloning site, MCS
(besides BamHI, underlined endonuclease sequence, other selective endonuclease sites at
MCS are: NdeI, HindIII, XbaI, XhoI and NotI) for single step cloning of any host protein.
The vector design originated by inserting the synthetic gene sequence (Genscript Inc.)
with the GST replacement, which was inserted using BtgI and NotI restriction enzymes.
The DNA sequence was verified by sequencing. The model host protein, interleukin-1α
(IL-1alpha, commonly known as hematopoietin 1 is a cytokine of the interleukin 1 family
which, in humans, is encoded by the IL1A gene) was cloned into pUARC-RUBY by
utilizing the MCS, namely the NdeI and XhoI cloning sites in the expression vector. The
final sequence of this construct was verified by DNA sequencing. Polymerase chain
reaction (PCR) was used to amplify gene specific primers, which code for the ArkRUBY-IL-1α. The vector that contains the 9×His-Ark-RUBY-IL-1α was then
transformed into E. coli cells. After obtaining confirmation of the nucleotide sequences,
protein was overexpressed in BL21(pLysS) E. coli cells cultured in 1 L of terrific broth
(TB) medium containing 500 μg/mL ampicillin and 500 μg/mL chloramphenicol. The
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induction of protein was accomplished by the addition of IPTG (final concentration 0.5
mM) when the OD at Abs 600 of the growing culture had reached 0.6. After 4 hours
incubation of the culture at 37 °C with agitation at 250 rpm, the cells were harvested and
lysed by ultra-sonication. The cell lysate was separated from the cell debris using ultra
centrifugation at 19,000 rpm. The same methods were followed for the expression of
Ark-RUBY-D2 and Ark-RUBY-AF by using Ark-RUBY-D2 and Ark-RUBY-AF genes,
respectively (Figure 1 & 2 panel A, B, & C & Figure 3).
Negative staining Transmission electron microscope
Bacterial pellets of 6×His-IL-1α, Ark-RUBY-IL-1α, 6×His-D2 and Ark-RUBYD2 were overexpressed in E. coli cells. The treated E. coli cells were resuspended with 10
mM PBS at pH-7.2. Each resuspended solution was spotted onto a Formvar and carboncoated copper grid (Electron Microscopy Sciences, USA). A 2% solution of Uranyl
acetate dissolved in distilled water (pH 4.2 to 4.5) was used to negatively stain the
samples. Uranyl acetate solution was filtered through a 0.22 µm filter before use. After 2
minutes, the remaining solution was removed with filter paper and the samples were
dried with filter paper. TEM images were taken at different magnifications by using high
resolution transmission electron microscopy (Jeol-HRTEM-2011, USA) with an
accelerating voltage of 80-100 kV.
Purification of recombinant Ark-RUBY-IL1α and IL-1α
Nickel (Ni2+)-Sepharose column (Amersham Biosciences, USA) was used for
purification of Ark-RUBY-IL-1α. The clear bacterial cell lysate was centrifuged for 25
minutes at 19,000 rpm 4°C. Then the supernatant was loaded on to a nickel (Ni2+)Sepharose column, and then the column was washed with 10mM PBS (phosphate
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buffered saline) at pH 7.2. A stepwise gradient of imidazole was used to elute all
proteins bound to the Ni2+-Sepharose column. The elution of proteins was monitored by
absorbance measured at 280 nm. Fractions collected at a concentration of 250 mM
Imidazole contain the Ark-RUBY-IL-1α protein. At that point, pure Ark-RUBY-IL-1α
was incubated with 100 NIH units of thrombin for 12 h (at 37°C) to cleave the affinity
tag. After that, thrombin cleavage products were reloaded onto a Ni2+-Sepharose column.
In order to elute IL-1α, the column was washed thoroughly with 10 mM PBS at pH 7.2
and a stepwise imidazole gradient was used. IL-1α was eluted in the 250 mM imidazole
fraction. The 250 mM Imidazole fraction was subjected to desalting by ultrafiltration
using a 10 kDa cut-off membrane. Then, the bound Ark-RUBY tag was eluted in 250
mM and 500 mM imidazole fractions. At each step, SDS-PAGE was performed to check
the purity. At the final point, IL-1α concentration was estimated by Abs 280 nm, using
the extinction coefficient value (Σ280 = 21430 M-1 cm-1) that is calculated from the
amino acid sequence of the protein.
Western-blot detection method
Purified Ark-RUBY-fusion proteins were resolved on 15% SDS-PAGE under
reduced conditions. The gel containing the fusion proteins was subjected to blot transfer
for western blot. Blotted/spotted nitrocellulose membrane was blocked using 5% skim
milk in 1x TBS-T (10mM tris, 100mM NaCl, 0.05% Tween-20; pH 7.4) at room
temperature for 1hr. Subsequently, the membrane was washed with 0.2% BSA in
1XTBS-T and the primary antibodies raised in goat against the His tag was added at
1:2500 dilution and incubated overnight at 4°C. Secondary antibody conjugated with
alkaline phosphatase that detects the IgG goat antibody was added to the membrane at
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1:2500 dilution and incubated for 2 hours at 4°C. The band on the membrane was
detected using the NBT/BCIP (Nitro-blue tetrazolium/5-Bromo-4-chloro-3-indolyl
phosphate) substrate within 60 seconds of exposure.
Purification of Ark-RUBY-AF by Heat treatment
The E. coli bacterial lysate was subjected to heat treatment at increasing
temperatures in a water bath from 25 °C to 90 °C (at 5°C intervals) for 10 minutes. All
samples were centrifuged at 13,000 rpm for 5 minutes to separate the aggregates from the
cell lysates. The results were revealed by SDS-PAGE gel for both samples (pellets and
lysates).
Far UV-Circular Dichroism study
All far UV-circular dichroism (CD) measurements were performed on a Jasco1500 spectrophotometer at 25 °C using a quartz cell with 1 mm path length with a scanspeed of 100 nm/sec. Each spectrum was an average of 3 scans. The concentration of
Ark-RUBY, Ark-RUBY-IL-1α and purified IL-1α were maintained as 20 μM. The final
spectrum was obtained after the subtraction of the corresponding buffer spectrum.
Equilibrium unfolding
The equilibrium unfolding experiments were performed on a Jasco-1500
spectrophotometer at 5°C intervals by using a concentration of Ark-RUBY- IL-1α,
purified IL-1α, and Ark-RUBY of 20 μM in 10 mM PBS at pH7.2. The unfolding process
of the proteins was monitored through changes of protein structure in the far-UV region
(190-250nm). Required background corrections were made for all spectra.
Biological activity assay
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Splenocytes were isolated from 6-12 weeks old C57BL/6J mice. The mice were
housed under pathogen free conditions and maintained in the microisolator cages. The
Institutional Animal Care and the Committee of the University of Arkansas approved for
raising of the mice. Animal care complied with the recommendations of the Guide for
care and use of Laboratory Animals (National Research Council). Dulbecco’s Modified
Eagle’s Medium (DMEM), RPMI 1640, Dulbecco’s Phosphate Buffered Saline (PBS),
and Fetal Bovine Serum (FBS) were obtained from HyClone Laboratories.

A

B

C

Figure 2: Panels- A, B, and C represent Escherichia coli codon optimized nucleotide
sequence and single letter coded amino acid sequence of Ark-RUBY-IL-1α, Ark-RUBYD2, and Ark-RUBY-AF [nucleotide sequence and corresponding amino acid sequence of
Ark-RUBY tag shown in red, thrombin and TEV cleavage site shown in blue, target
recombinant IL-1α, D2, and AF shown in black].
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1001 CCCGCTCNTTCGCTTTCTTCCCTTCNTTCTCGCCACGTTCGCNGCTTTCC

1050

514 --------------------------------------------------

513

1051 CCGTCAAGCTCTAATCGGGGCTCCCTTTAGGGTTCCGGATTTAGTGCTTA

1100

514 --------------------------------------------------

513

1101 CGGCACTCGACCCCAAAAAACTNGATAGGTGATNNNNCGTANNGGNNNAN

1150

514 ---------------------------------------------

513

1151 NNNGGATAGACGNNNTTTCNNCNTNNCCNTTGGNNTNNNGNTNNT

1195

Figure 3: Represents experimental confirmation of the DNA sequence of human IL-1α.
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Results & Discussion
Ark-RUBY prevents the formation of Inclusion bodies Ark-RUBY-IL-1α and ArkRUBY-D2-FGFR1 are each overexpressed in E. coli as soluble proteins. In contrast,
6×His-IL-1α and 9×His-D2-FGFR1 were completely expressed as insoluble inclusion
bodies. Transmission Electron Micrographs (TEM) of E. coli cells, induced by Isopropyl
β-D thiogalactoside show that 6-His-IL-1α and 9xHis-D2-FGFR1 are overexpressed as
dense and opaque inclusion bodies (Figure 4, Panel A and C). However, TEM data of the
E. coli cells overexpressing Ark-RUBY-IL-1α and Ark-RUBY-D2-FGFR1 are mostly
clear and do not show formation of inclusion bodies (Figure 3, Panel B and D).
B

A

C

D

Figure 4: Panels-A, B, C and D represent selected negatively stained TEM images of 6×HisIL1-α, Ark-RUBY-IL-1α, 6XHis-D2, and Ark-RUBY-D2-FGFR1, overexpressed in E. coli
cells. Scale bar is 500nm.
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Color of the bacterial lysate containing overexpressed Ark-RUBY-target
protein/peptide The bacterial lysate of Ark-Ruby tagged target proteins is pale to bright
Ruby red (Figure 5). The RUBY red color of the bacterial lysate can be used as a reliable
indicator of the overexpression of the Ark-RUBY tagged recombinant proteins/peptides
and can be followed during. Data on the purification and characterization of recombinant
IL1-α is elaborated subsequently in this study.

Figure 5: showing the Ruby red color of bacterial lysate of Ark-Ruby tagged target
protein.
Ark-RUBY-IL-1α can be purified using Nickel-Affinity chromatography Both ArkRUBY-Pro and Ark-RUBY-Pep clones contain an N-terminal 6xpolyhistidine tag and so
are amenable to nickel (Ni)-affinity chromatography using an imidazole gradient. A
ruby-red band formed when the bacterial lysate, containing overexpressed Ark-RUBYIL-1α was loaded on the Ni-sepharose column. The movement of the ruby-red band
corresponding to Ark-RUBY-IL-1α can be followed during the purification process
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(Figure 6, Panel A). The elution profile of Ark-RUBY-IL-1α in different imidazole
fractions is shown in Figure 7, Panel B.

A

B

Figure 6: Panel-A showing the red color of Ark-RUBY tag fused to IL-1α, on Nickel
(Ni2+)-Sepharose column. Panel-B represents elution profile of proteins contained in
the supernatant, obtained by using stepwise imidazole (IMD) gradient. The profile
depicts that the protein fractions eluted at different concentrations (20mM, 50mM,
100mM, 250mM and 500mM) of imidazole (IMD). Ark-RUBY-IL-1α is eluted at
250mM concentration of imidazole.
Ark-RUBY-IL-1α eluted completely in 250 mM imidazole fraction. SDS-PAGE of the
eluted fractions revealed an intense band in the 250 mM fraction with a molecular mass
(25kDa), which matches with that of Ark-RUBY-IL-1α (Figure 6, Panel A).
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Figure 7: Purification of Ark-RUBY-IL-1α on Nickel (Ni2+)-Sepharose column.
Elution of proteins in the supernatant was obtained by using a stepwise imidazole
gradient. Panel- A shows SDS-PAGE gel of protein fractions eluted at different
concentrations of imidazole as detected by Coomassie blue. Lane 1, Pellet (P); Lane 2,
Supernatant; Lane 3, 20mM imidazole; Lane 4, 50mM imidazole; Lane 5, 100mM
imidazole, Lane 6, 250mM imidazole; Lane 7, 500mM imidazole; PM, Protein
molecular weight marker. Purified Ark-RUBY-IL-1α is eluted at 250mM imidazole
concentration with corresponding molecular weight 25kDa. Panel-B represents
Coomassie blue stained SDS-PAGE of Ark-RUBY-IL-1α reloaded on Ni-sepharose
affinity chromatography after thrombin treatment. Lane 1, Ark-RUBY-IL-1α (before
thrombin treatment); Lane 2, thrombin-cleaved Ark-RUBY-IL-1α eluted at 250mM
imidazole Concentration ( upper band corresponds to IL-1α and lower band
corresponds to Ark-RUBY tag); After desalting 250mM imidazole fraction, the lower
band is completely removed. Lane 3, Ark-RUBY tag is eluted at 500 mM imidazole
concentration.
Coomassie blue and Silver staining data revealed that Ark-RUBY-IL-1α is > 98% pure
(Figure 8, Panel A and Panel B). It should be mentioned the 6X polyHistidine-IL-1α is
invariably expressed in inclusion bodies. Subsequent attempts to recover 6x polyHisIL1α from the urea-denatured inclusion bodies was futile and did not yield any detectable
amounts of the recombinant fusion protein. These results suggest that the Ark-RUBY tag
not only thwarts the overexpression of the target protein(s) as inclusion bodies but also is
amenable as an efficient purification method using Ni-affinity chromatography.
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A

B

C

Figure 8: Panels- A and B represent Coomassie blue and silver stained SDS-PAGE of
Ark-RUBY-IL-1α and thrombin-cleaved Ark-RUBY- IL-1α. Panel-C represents
western blot of Ark-RUBY-IL-1α and thrombin-cleaved Ark-RUBY- IL-1α. Lane PM
is the protein molecular weight marker. Coomassie blue staining, silver staining and
western blot show a band (Mw ~17kDa) corresponds to pure IL-1α after thrombin
cleavage.
Ark-RUBY tag can be successfully separated from the target recombinant
protein/peptide Ark-RUBY-IL-1α has a -LVPRGS-thrombin cleavage site. Therefore,
purified, Ark-RUBY-IL-1α was treated with thrombin at 37 °C. An additional
chromatographic step of the thrombin cleaved products on Ni-sepharose showed that
recombinant IL-1α elutes as expected in the 250 mM imidazole fraction with a small
amount of Ark-RUBY tag but this band is completely eliminated during desalting and
concentration of the 250 mM fraction by ultrafiltration using a 10 kDa cut-off membrane.
The Ark-RUBY tag, due to the presence of the 6X poly-Histidine tag, is bound to the Nisepharose column and is subsequently eluted at 500 mM (Figure 7, Panel A). Coomassie
blue staining, silver staining and Western blot of the 250 mM imidazole fraction shows a
pure band corresponding to recombinant IL-1α (Figure 8, Panel B and Panel C). The final
yield of pure recombinant IL-1α is 12 mg per liter of the bacterial culture. These results
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clearly show that the linker between Ark-RUBY and the recombinant target protein (IL1α) can be successfully cleaved and IL1-α can be subsequently purified by Ni-sepharose
chromatography.

Ark-RUBY tag can be successfully used for the elimination of significant
contaminants remaining after employing Nickel-Affinity chromatography for
purification of heat stable proteins Ark-RUBY tag is a thermostable tag (Tm > 90C).
Owing to the excellent thermostability property of the Ark-RUBY tag, it is selectively
used for the purification of heat stable recombinant proteins. Interestingly, if some strong
contaminants were to be observed after employing Ni-affinity chromatography, they can
be completely eliminated by thermal treatment. For example, the Ark-RUBY-D2 clone
contains a N-terminal 6X poly-histidine tag and when subjected to purification using
nickel (Ni)-affinity chromatography using a stepwise imidazole gradient showed an
intense band in the 250 mM fraction (whose molecular mass (21 kDa) matched with that
of Ark-RUBY-D2) along with some strong lower and higher molecular weight
contaminant bands (Figure 9, Panel A). Those bands were completely eliminated by
thermal treatment of the 250 mM fraction to 65°C. Coomassie blue staining revealed that
Ark-RUBY-D2 showed that the fusion protein is > 98% pure (Figure 9. Panel B). These
results suggest that Ark-RUBY tag can also be successfully used for the cost-effective
production of heat stable recombinant proteins.
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Figure 9: Purification of Ark-RUBY-D2 on Nickel-Sepharose column. Panel- A
represents Coomassie blue stained SDS-PAGE gel of the protein fractions, eluted at
different concentrations of imidazole. Lane 1, Pellet; Lane 2, Cell culture supernatant;
Lane 3, 20mM imidazole; Lane 4, 50mM imidazole; Lane 5, 100mM imidazole; Lane
6, 250mM imidazole; Lane 7, 500 mM imidazole; PM, protein molecular weight
marker. SDS-PAGE showed that 250mM imidazole fraction contains band for ArkRUBY- D2 with contaminant bands and molecular weight of Ark-RUBY- D2 matches
with ~21kDa. Panel-B represents Coomassie blue stained SDS-PAGE of 250mM
imidazole fraction after heat treatment at 65 °C for 20 min. Lane 1, 250 mM imidazole
fraction before heat treatment, Lane 2, pure Ark-RUBY-D2 (Mw ~21kDa) after heat
treatment of 250mM imidazole fraction at 65 °C for 20 min; PM, protein molecular
weight marker.
Ark-RUBY tag can be used for the purification of peptides in a single step without
the use of sophisticated column chromatography techniques Ark-RUBY-FGF peptide
and Ark-RUBY-Antifungal peptide (Ark-RUBY-AF) can be purified without the use of
multiple purification steps. Purification of the Ark-RUBY-Antifungal peptide is
elaborately described in this section. The E. coli bacterial lysate, obtained from 1 Liter of
culture, was systematically heated in a water bath from 25 °C to 90 °C (at 5 °C intervals)
and the precipitate obtained at each temperature was removed by centrifugation. Analysis
of the supernatant by SDS-PAGE revealed that only Ark-RUBY-Antifungal peptide
remained in solution (in the supernatant) as a pure single band at and beyond 75°C
(Figure 10, Panel A). The presence of Ark-RUBY-Antifungal peptide is determined from
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the ruby-red color of the supernatant. Coomassie blue staining of the supernatant fraction,
obtained from 75°C-90°C, showed that the peptide is pure. These results suggest that
Ark-RUBY-heat stable target peptides can be purified in single-step without the use of
expensive chromatography techniques. This simple heat-induced purification is very
applicable to recombinant peptides because peptides, which are mostly either
unstructured or have simple higher order structure(s), are known to undergo reversible
thermal unfolding.
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Figure 10: Purification of Ark-RUBY-AF by heat treatment without the use of column
chromatography techniques. Panel-A represents Coomassie blue stained SDS-PAGE of
E. coli bacterial lysate (supernatant) after heating from 25 °C to 90 °C. Coomassie blue
staining showed that Ark-RUBY-AF remained in the supernatant as pure single band
(Mw~12kDa) at and beyond 75 C. PM is the protein molecular weight marker. PanelB represents precipitated component (pellet) after heat treatment of E. coli lysate from
25 °C to 90 °C.

52

Recombinant IL-1α is in the native conformation Far UV-circular dichroism is a
popular biophysical technique that is commonly used for the determination of the
secondary structure of proteins. Far UV-CD spectrum of pure Ark-RUBY-IL-1α is
characteristic of a helical conformation with a double minimum at 208 nm and 222 nm
(Figure 10, Panel A). Upon separation of Ark-RUBY, pure recombinant IL1α shows a
negative peak at 208 nm and a prominent positive peak in the range of 225 nm-230 nm,
which is reminiscent of the native beta-barrel fold of IL-1α (Figure 11, Panel B).
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Figure 11: Panels- A and B represent far-UV CD spectrum of Ark-RUBY-IL-1α and
IL-1α in 10mM PBS at pH-7.2 respectively.
Ark-RUBY-Tag is Thermostable tag Thermal denaturation of pure recombinant ArkRUBY, Ark-RUBY-IL-1α, and IL-1α was monitored by Far UV-circular dichroism based
on ellipticity changes at 228 nm. Ark-RUBY-tag showed high thermal stability since the
secondary structure of the tag did not change at both temperatures at 25°C and 90°C.
Even though at both temperatures the Ark-RUBY- IL-1α showed similar secondary
structure, the intensity at 90°C compared to the intensity at 25°C was low (Figure 12).
Interleukin 1 alpha was completely unfolded at 90°C. These results suggest that the
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purified recombinant IL-1α is a well-folded and stable protein when it is attached to the
thermal stable tag.
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Figure 12: Represents the circular dichroism of Ark-RUBY-tag, Ark-RUBY-IL-1α, and
IL-1α, and at 25°C & 90°C. The changes of the secondary structure monitored by
recording the shifting of the positive peak at 228 nm and negative peak at 205nm for
IL-1α. However, for both Ark-RUBY-IL1α and Ark-RUBY tag, the secondary
structural changes were monitored by recording the shifting of the negative peak at 208
and 222 nm.
Interleukin 1 alpha that is expressed fused with the Ark-RUBY-tag is biologically
active The biological activity was assessed to ensure that the purified recombinant IL-1
is in the biologically active conformation. IL-1α has a strong effect on splenocytes that
are derived from C57BL/6Jmice. IL-1α is known to stimulate the secretion of IFN-γ from
splenocytes51. Therefore, the secretion of IFN-γ was used as a measure of bioactivity of
IL-1. Splenocytes were plated on a 96-well plate in the presence and absence of IL-1α
(0-50 ng/mL). The secreted IFN-γ activity in the supernatant was measured after 24 hours
by using enzyme-linked immunosorbent assay (ELISA). The concentration of IFN-γ was
found to increase significantly upon exposure to 0.0032 to 50 ng/mL of IL-1α (Figure
13). These results suggest that the purified recombinant IL-1α is biologically active.
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Figure 13: Represents the production of IFN-γ by splenocytes upon addition of IL-1α
(0-50ng/mL). The calculated standard errors were derived from triplicate
measurements.

Conclusions
Overexpression and purification of IL-1α in large quantities has been a challenge for
performing detailed biophysical studies. IL-1α is very unstable, which leads to the
degradation of the protein. Expressing IL-1α in a heterologous host such as E. coli was
challenging. Herein, for the first time, recombinant IL-1α was produced in E. coli cells
attached to rubredoxin using a simple IMAC SepharoseTM affinity chromatography. One
of the most popular methods to purify recombinant proteins from a wide range of
expression hosts is affinity chromatography. The method relies on the incorporation of
selective protein or peptide affinity tags which are aligned in sequence to the target
protein gene to produce the target fusion protein. This unique expression procedure
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allowed for the acquisition of homogeneously pure IL-1α in order to perform various
biophysical.
Rubredoxin (Rd) from Pyrococcus furiosus has unique and interesting properties
which can be profitability exploited as an excellent recombinant protein purification tag.
It exhibits a bright red color due to oxidation of the central iron atom in the iron-sulfur
core. The red color of Rd will help to track the Rd-fused target recombinant protein
during purification as it was shown in Ark-RUBY- IL-1α. The smaller molecular mass of
Rd will reduce the possibility of its interference with the folding of the target protein. Rd
proteins have an exceptionally high thermal stability (Tm > 90°C). The extraordinary
thermal stability of Rd can likely be used to rapidly eliminate contaminating proteins
from the expression host by heating the bacterial cell lysate. This aspect can be expected
to significantly shorten the time duration required for the purification of Rd-fused
recombinant proteins/peptides. Rd is known to be highly soluble protein. The high
aqueous solubility of Rd can potentially facilitate the overexpression of the Rd-fused
recombinant protein/peptide in their soluble form by preventing the formation of
unproductive inclusion bodies. The advantage of using CNBr is that it eliminates the
requirement of using expensive restriction proteases for separating the
affinity/purification tag from the recombinant target protein. Another positive feature of
the CNBr-induced cleavage of methionine-less Rd-fused target protein(s) is that it does
not leave any extra amino acids, from the tag or the linker, on the target recombinant
protein/peptide52.
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Chapter Three
Characterization of the copper-induced dimer of Interleukin 1-alpha
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Abstract
Most secreted proteins have a hydrophobic cleavable signal peptide in their primary
structure which guides their translocation into the lumen of the endoplasmic reticulum (ER).
After vesicular transport through the ER-Golgi, secreted proteins are released into the
extracellular compartment. This route of protein export is known as the classical secretion
pathway. However, many extracellular proteins have shown to be secreted through ER-Golgiindependent (non-classical) pathways. A common feature of non-classically secreted proteins is
the absence of a signal peptide. The prototype member of the interleukin 1 family, interleukin 1
alpha (IL1) is a signal-less protein that is secreted via the non-classical secretory route. IL1α
is a multifunctional pro-inflammatory cytokine. It is a key mediator in the cytokine network,
regulating crucial functions in the immune response, inflammation, tissue remodeling, cell
differentiation, and cell death. This study indicated that copper (Cu++) binds to IL1α with high
affinity and induced the formation of an IL1α dimer via the formation of an intermolecular
disulfide bond. Also, the dimer formation did not alter the backbone conformation of the
protein, although it displayed decreased bioactivity. Also, the dimer form as well as the
monomer form of IL1α both exhibit high affinity to S100A13. The Cu2+ binding sites in IL1α
were mapped by 2D HSQC spectroscopy. The HSQC data showed that many amino acids
residues are perturbed by Cu++ binding.
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Introduction
In living systems, many metals play crucial roles in cellular processes including
inflammation, cells differentiation, anti-oxidant activities, and blood homeostasis1, 2.
Calcium, zinc, copper and iron are co-factors which are involved in the activation of
several biological reactions3, 4. Some of them have harmful effects on cells, but these
metals are important for vital functions. Copper is involved in different biological
processes including the production of neurotransmitters, connective tissue remodeling,
anti-free radical reactions, and pigment development 5, 6. Recent studies have
demonstrated that copper acts as angiogenic molecules by regulating the secretion of
FGF1 and IL-1α7. Also, some clinical data have suggested that using copper chelators
helps in minimizing cancer progression7-9. Copper ions can have damaging effects on
cells because it can easily exchange electrons leading to interference with cellular
respiration, neuronal differentiation, and signal transmission. Many protein chaperons are
involved in regulation of intracellular and extracellular copper trafficking10. In
intracellular compartments, many proteins are known to bind to copper and serve as
copper chaperons such as Atox1, CCS and Cox17, but still the mechanism of delivering
copper for cellular processes is not clear11. In unconventional protein secretion of FGF1,
copper plays an important role by binding to S10A13 and dimerizing FGF-1 by oxidizing
cys3012. Copper induced FGF1 dimerization is crucial for non-classical protein
secretion13, 14. Interestingly, IL-1α lacks the N-terminal signal peptide that mediates the
secretion through the Endoplasmic-Golgi apparatus system (ER-Golgi system)15, 16. The
ER-Golgi system is the route for moving proteins out the cells. The ER-Golgi
transformation system needs a signal peptide that directs proteins to their final
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destination17. IL-1α is secreted by unconventional protein secretion (UPS) into an
extracellular compartment to exert its actions by binding to IL-1R118, 19. UPS is induced
but not exclusively by cellular stress such as inflammation, starvation, autoimmune
diseases and ER stress. Even though many proteins like FGF1, FGF2, IL-1β, and calcium
binding protein S100A13 are released by UPS, the mechanism(s) that triggers the release
of signal peptide-less proteins is still not understood20-22. Many studies have shown that
copper (Cu2+) is involved in unconventional protein secretion of many proteins such as
FGF1 in response to heat shock and hypoxia23-25. Also, using copper chelating agents for
example, tetrathiomolybdate, decreases the release of FGF1 that helps in the suppression
of tumor growth 26. Many studies have confirmed that FGF1 and IL-1α share structural
homology as well as being released by the UPS route27, 28. Surprisingly, S100A13, an
important component of stressreleased FGF1, is also mandatory for unconventional
protein secretion of IL-1α29. Also, S100A13 is known to bind to Cu2+ as well as
calcium30, 31. It is believed that Cu2+ may be involved in unconventional protein secretion
of IL-1α. Thus, it is important to define and understand the mechanism that underlies the
export of IL-1α by unconventional protein secretion since it medically assists in the
management of inflammatory and carcinogenic disorders that are caused by IL-1α. The
results of this study revealed that IL-1α has high binding affinity for copper. Copper
induced IL-1α dimerization is mediated by the oxidation of the lone Cys143. The dimeric
form of IL-1α shows similar properties as the monomer but exhibits lower activity.
Materials and Methods
Materials VWR Scientific Inc, USA was the provider for all buffer components
including Na2HPO4, NaH2PO4, NaCl. Lysogeny broth (LB) was purchased from EMD
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Millipore, USA. Competent cells (DH5α and BL-21p-LysS (DE3)) were obtained from
Novagen Inc., USA. DNA plasmid isolation kits were bought from Qiagen, USA and
Quikchange II XL mutagenesis kits were purchased from Agilent. Nickel sepharose was
acquired from GE Healthcare, USA.
Expression and Purification of Recombinant S100A13
For expression of S100A13, BL-21 Star (DE3) cells transformed with the
expression vector pGEX-GST-S100A13 were grown at 37⁰C in one liter of culture of
Luria broth containing 100 μg/ml Ampicillin. The protein expression was induced with 1
mM isopropyl β-thiogalactoside for four hours after the optical density at Abs600 nm
reached 0.4-0.6. Then, cells were harvested by centrifugation at 8000 rpm for 25 minutes,
the pellet was suspended in 30 mls 10 mM phosphate buffer PH 7.2 and sonicated. GSTS100A13 was bound to glutathione Sepharose that was then washed successively with 10
mM phosphate buffer PH 7.2. Overnight cleavage on column was setup at room
temperature on a rocker with thrombin protease for 16 hours. The cleavage product was
washed with 10 mM phosphate buffer PH 7.2 to collect the cleavage product (S100A13).
The GST tag was eluted using 10 mM L-Glutathione. The expression of GST-S100A13
and the cleavage product of S100A13 were checked by SDS-PAGE stained with
Coomassie blue.
Far-UV Circular Dichroism Spectroscopy
Far-UV CD measurements were accomplished using Jasco 1500
spectropolarimeter at 25οC, and a protein concentration of 0.5 mg/mL in 10mM
phosphate buffer (pH 7.2) using 0.1 mm bath length. All data were smoothed using the
Savitzky-Golay algorithm.

66

Limited Trypsin Digestion (LTD)
LTD experiments were done by incubating protein samples with enzyme at pH
7.2 in 10 mM phosphate buffer at 37°C. The samples were collected after each ten
minutes and the reactions were stopped immediately by adding 10% trichloroacetic acid.
By running the samples on 15% SDS-PAGE, the results were analyzed by measuring the
intensity of the digested protein by trypsin bands at different points of time using
densitometric scan [UN-SCAN IT (Silk Scientific Inc., USA)]. Then the calculated
values of bands intensities were compared with the zero-time Coomassie blue stained
protein band.
Isothermal titration calorimetry (ITC)
ITC (iTC-200, Malvern Inc.) was used to determine the IL-1α (monomer or dimer
form)-S100A13 and IL-1α-CuCl2, and different metals binding affinity. By titrating the
ligand (loaded in the syringe) into protein solution in the reaction cell, heat changes were
measured. All protein and metals samples were prepared in solution containing 10 mM
HEPES buffer (pH 7.2) then all samples were degassed prior to titration. ITC experiment
parameters performed were 30 titration injections, at 25°C with a stirring speed of 750
rpm. ITC binding curves were best fits using one set of binding models followed by
appropriate corrections to eliminate the heats that were generated from the dilution.
Extrinsic Fluorescence Spectroscopy
Extrinsic fluorescence experiments (ANS binding assays) were performed using a
Hitachi F-2500 fluorescence spectrophotometer at 25°C. A protein concentration of 0.5
mg/mL in 10 mM phosphate buffer, pH 7.2 was used in all fluorescence experiments. All
fluorescence measurements were recorded using the slit width set to 2.5 nm, excitation
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wavelength of 280 nm, and emission wavelength range from 300-450 nm. Performing
ANS binding assays, the titrations were carried out by adding 1μL of ANS. The relative
fluorescence intensity records were made at 510 nm.
Equilibrium unfolding of Proteins
Far-UV Circular dichroism (Jasco-1500) was used to study thermal and chemical
denaturation experiments. In thermal unfolding studies, the protein concentration of the
samples was 0.5 mg/ml in 10 mM phosphate buffer, pH 7.2. Spectra were collected from
25°C to 90°C at five-degree intervals. To calculate Tm value where 50% of protein
population is in the unfolded state(s), a plot was generated from fraction unfolded protein
population versus temperature. The Cm where 50% of protein population was in unfolded
state(s) was calculated by plotting each spectrum verses urea concentrations. Ureainduced equilibrium unfolding of protein samples was analyzed using the fluorescence
mode of Jasco-1500 spectrometry. Protein concentration of the sample was 0.5 mg/ml in
10 mM phosphate buffer at pH 7.2.
Nuclear Magnetic Spectroscopy
1H-15N

heteronuclear signal quantum coherence (HSQC) were performed on

Bruker 700 MHz NMR, at 25°C. The protein concentration was 350 μM in 10 mM
phosphate buffer (pH 7.2). M9 media was used to grow the bacterial hosts of IL-1α in
which the nitrogen source was isotopes 15NH4Cl. Sparky 3.114 software was used to
analyze 2D NMR data of labeled IL-1α.
Bioactivity assay
HEK-BlueTM IL-1α/IL-1β cells (Invivogen) allow monitoring the bioactivity of
IL-1α and IL-1β by activation of the NF-kB and AP-1 pathways. The response to TNF- α
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is blocked, so the cells are responsive only to IL-1. The binding of IL-1 to cell surface
receptors triggers specifically the NF-kB cascade leading to producing the secreted
embryonic alkaline phosphatase (SEAP). A 96-well plate was seeded with 50,000
cells/well of HEK-BlueTM IL-1α/IL-1β cells, then the cells were treated with media
containing 0.4 to 10 ng/ml IL-1α or copper induced IL-1α dimerization. Supernatant
SEAP concentrations were detected by quantifying Quanti-BlueTM (Invivogen) via
reading the wells at 650 nm.
Results and discussion
Copper dimerizes Interleukin-1 alpha
In order to examine the effects of copper on IL-1α, CuCl2 was incubated with IL1α at room temperature. One migrating band resolved when IL-1α in the absence of
copper was run and two bands of IL-1α-copper complex were migrated through nonreduced SDS-PAGE representing the monomer and the dimer (Figure 1). In contrast to
the monomer, double bands appeared when the same concentration of IL-1α was treated
with 30 μM CuCl2. For calculating the copper concentration that induces complete
protein dimerization, IL-1α was treated with different concentrations of CuCl2. Then, IL1α was electrophoresed in non-reduced SDS-PAGE. Dimer band of IL-1α appeared even
at a low concentration of CuCl2. The intensity of dimer bands increased while the
concentration of CuCl2 increased. Compete dimer band displayed with no monomer band
left at 46 μM CuCl2 (Figure 2).
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IL-1α

IL-1α +Copper

Dimer

Monomer

Figure 1: illustrates Non-reduced SDS-PAGE that revealed the dimer formation of IL-1α
after treating it with CuCl2. Uncompleted dimerization of IL-1α under influence of
particular concentration of CuCl2 indicates that some proteins were at monomer form.

Figure 2: demostrates the dimer formation and monomer reduction of IL-1α while CuCl2
concentrations are increasing. The concentrations of CuCl2 in (μM) are shown above each
band. A: The dimer form of IL-1α appeared at a low concentration of CuCl2. C: Both
monomer and dimer form of IL-1α appeared on the non-reduced SDS-PAGE. C: The
maximum concentration of CuCl2 for complete dimerization is 46 μM CuCl2. D: the
densitometric scan of the SDS-PAGE gel that shows the dimer formation versus the
monomer form of IL-1α in presence of different concentrations of CuCl2.
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These results indicated that specific disulfide bands were formed between two
cysteine amino acids of different monomers of IL-1α. We propose that forming the dimer
form of IL-1α is relatively important for some biological activities. It may explain that
the IL-1α might be released at high volume to reach maximum effects.
Secondary structure of IL-1alpha does not alter upon copper-induced dimerization
The secondary structure of IL-1α belongs to β-trefoil family that is one of the ten
of protein super families32. Several proteins types that are included in this family such as
FGF-1, FGF-2, IL-1β, and soybean trypsin inhibitors33. IL-1α consists of twelve β
strands that are arranged into trefoil units called hairpin. The twelve β-strands are folded
into three similar trefoil units of β-β-β-loop-β32. Circular dichroism is a valuable
technique for examining the secondary structure changes induced in protein-protein
interaction. CD spectra of the dimer form of IL-1α gets overlaid well (Figure 3)

Figure 3: Far-UV spectra of the monomer form of IL-1 α (orange dots) and the dimer
form of IL-1 α (blue dots).
with the monomer type, displaying the quality feature of the positive ellipticity shoulder
in the wavelength range 220-240 nm, and a negative shoulder in the region of 200-210
nm. These spectral characters indicate that the native β-trefoil conformation is not
significantly disturbed because of the dimer formation.

71

No conformational changes in three-dimensional structure upon copper induced
dimerization of IL-1α monitored by (ANS) binding assay
The tertiary structural changes of proteins were examined by using the ANS
binding assay. ANS is hydrophobic, non-polar dye that has been used to study proteins
conformational changes. Polar amino acids make hydrogen bonds with water whereas
non-polar and aromatic amino acids are hydrophobic and are usually buried inside the
core of the protein(s)34. Upon protein-protein interaction, hydrogen bonds are formed
between two reactants that cause conformational changes. Monitoring ANS binding,
conformational changes can be analyzed. The extrinsic fluorescent probe of ANS binds to
solvent accessible hydrophobic surface(s) in the proteins 35. In this context, measuring the
changes of ANS fluorescence helps to study structural differences between the monomer
and the dimer form of IL-1α (Figure 4).
ANS binding curave of the monomer and the dimer of IL-1 alpha
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Figure 4: ANS binding curve of the monomer form of IL-1 α & the dimer form of IL-1 α
Typically, hydrophobic portion(s) of proteins are buried in the protein core, so
increasing ANS fluorescence suggests more solvent accessible hydrophobic surface(s)
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are present. The emission intensity of ANS binding to the dimer form of IL-1α is higher
than the monomer form when it binds to ANS. This indicates that induced dimerization
encourages a modest conformational change causing an increase in the solvent-exposure
of the hydrophobic surfaces(s).
No conformational changes upon copper induced IL-1α dimerization detected by
Limited Trypsin Digestion (LTD)
Trypsin is a serine protease that cleaves at the carboxyl terminal end of lysine and
arginine residues. Many factors affect the rate of the protease-substrate cleavage reaction
including number of hydrogen bonds between the cleavage sites, the degree of protease
accessible to the cleavage site, degree of protein folding, and flexibility of the substrate36.
In this context, the LTD assay is a useful technique to study protein flexibility and
possible structural changes in the protein backbone caused by protein dimerization. LTD
was performed on the monomer and the dimer form of IL-1α to determine any
conformational and flexibility changes of the dimer form compared to the monomer
form. The progress of the cleavage reaction of the substrates was determined by
comparing the measurements of the intensity of the zero trypsin, non-cleaved band at 19
kDa (monomer) and 38 kDa (dimer) Coomassie blue stained bands on SDS-PAGE with
trypsin-substrates bands at different time periods. Based on the digestion rate of the
monomer and the dimer form of IL-1α, both showed higher susceptibility to trypsin
(Figure 5). The monomer form of IL-1α began cleavage by trypsin after five minutes of
incubation until fifty percent of Cu2+ free IL-1α was cleaved after 30 minutes from the
initiation time. Copper induced IL-1α dimerization showed better stability than the
monomer form. The dimer was stable till twenty minutes of incubation then cleavage
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started gradually after 30 minutes until fifty percent of the dimer became cleaved after 50
minutes.
Trypsin Digestion of the monomer and the
dimer of IL-1 alpha

Dimer

% Undigested

120
100

Monomer

80
60
40
20
0
0

10

20

30

40

50

60

Time (minutes)
Monomer

Dimer

Figure 5: Densitometric analysis of the SDS-PAGE gel analyzing the flexibility of the
monomer and the dimer form of IL-1α.
The monomer form of IL-1α showed higher vulnerability to trypsin than the dimer form
which suggests that the dimer form is more tightly packed. These results indicate that the
dimer formation of IL-1α has better stability effects on the flexibility of the backbone.
Copper induced IL-1α dimerization alters the stability of the protein
Metal binding induces conformational changes that alter the stability of the protein. It is
important to investigate the properties of metal binding effects in order to understand the
physiological role(s) that are changing the functional characteristics of the proteins. In
this context, thermal denaturation was performed to analyze the effects of copper on
thermodynamic stability of protein dimerization. Far UV CD spectroscopy was used to
measure the thermal stability of the monomer and the dimer forms of IL-1α. The thermal
denaturation of the monomer form of IL-1α was examined by analyzing the fraction
unfolded at 228 nm (Figure 6).
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Figure 6: shows thermal stability of IL-1α forms (monomer and dimer).
The monomer form of IL-1α began unfolding at temperature 50°C and it was
completely unfolded at 90°C. In order to analyze the denaturation temperature, the
melting point (Tm) value should be determined. Tm is the temperature at where 50% of
the protein population exists in the denatured state. The Tm value of the IL-1α in
monomer states is at 60°C. Interestingly, the copper induced IL-1α dimerization form
shows remarkable thermal stability. The thermal stability of the dimer form increases to
which the protein starts unfolding at 60°C. The melting point of the dimer form is 70°C.
The results suggest that the compact protein structure of the dimer form improved leading
to increase the stability of the protein. Also, the formation of disulfide bonds helps in
increasing the stability of the dimer form of IL-1α.
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Copper induced IL-1α dimerization increases protein chemical stability
In order to complete the protein stability investigation, chemical denaturation was
monitored to study the influence of metal binding on protein conformation. It is known
that metals alter the mass of hydrogen bonds across the protein core. The Chemical
stability was also measured using Far UV CD spectroscopy for the monomer and the
dimer forms of IL-1α. The metal binding conformational changes were analyzed by
measuring the fractions unfolded for both IL-1α forms to calculate chemical denaturant
melting point (Cm). Cm is the concentrations at which 50% of the proteins are in
denatured state. Urea was used to study the effect of metal binding on the chemical
stability of proteins (Figure 7).

Figure 7: displays the chemical stability of IL-1α in two forms (monomer and dimer).
Urea is known as a non-ionic denaturant salt which breaks hydrogen bonds. The
unfolding state of the monomer form of IL-1α began at a urea concentration of 2.18 M
and the protein was completely unfolded at a urea concentration of 4.29 M. The Cm
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value of the monomer form was 3.5 M. Interestingly, the copper induced IL-1α
dimerization showed that the unfolded state started at a concentration of 3.5 M urea and it
was entirely unfolded at 4.85 M. The Cm value of the dimer form was 4.5 M. This result
indicates that copper binding to the protein stabilizes the protein by increasing the
hydrogen bonds and decreasing the protein surface exposed to the solvent.

Cysteine 143 mediates disulfide-liked dimerization of IL-1α
FGF1 is released from NIH 3T3 cells as a biologically inactive homodimeric form
in response to heat shock. During heat shock, the cysteine residues of FGF1 are important
in the non-classical secretion mechanism since FGF1 free cysteine residues are not
released in response to stress37. Also, in non-classical secretion of peroxiredoxine 1 and 2
that do not have signal peptides, cysteine residues mediate the protein dimerization in the
cytoplasm and during the protein translocation outside of the cells38. To gain further
insight into understanding the non-classical protein secretion of IL-1α, and since IL-1α
has only one cysteine; we attempted to determine whether or not Cys143 is essential in
protein dimerization. The cysteine residue was mutated to serine, as both amino acids are
similar except the sulfur thiol atom in cysteine is replaced with oxygen in serine. The
single IL-1α C143S mutant was overexpressed using the same conditions that were
applied in producing the wild type of IL-1α. The IL-1α C143S mutant was successfully
overexpressed and the secondary structure of the mutant IL-1α matched that of the wild
type. Treating the mutant IL-1α with CuCl2 did induce IL-1α dimerization. The results
suggested that cysteine oxidation mediates the formation of a disulfide linked dimer of
the wild type IL-1α whereas IL-1α free cysteine failed to present the dimer form.
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Figure 9: SDS-PAGE showed A: the wild and the mutant proteins have the same
molecular weight. B: The secondary structure of the mutant overlays on the wild type of
IL-1α. C: Copper induced wild type of IL-1α whereas the copper did not dimerize the
mutant.
Interleukin 1 alpha is a copper binding protein as monitored by isothermal titration
calorimetry (ITC)
In this study, ITC was used to examine the affinity of IL-1α not only to CuCl2 but
also to different metals such as CaCl2, FeCl2, NiCl2, CuCl, MnCl2, ZnCl2, CoCl2, CdCl2
and MgCl2 (Figure 10). ITC revealed that the type of interaction of IL-1α and CuCl2 is
exothermic and the reaction has negative enthalpy. The binding curve of the IL-1α and
CuCl2 is hyperbolic. The binding constant (Kd) was calculated after applying a best-fit
model. The Kd value of the IL-1α to CuCl2 was 1.9 μM. ITC results demonstrate that
copper interacts with IL-1α at high affinity which causes conformational changes. These
data are in good agreement with copper induced IL-1α dimerization, and protein stability
experiments as well as ANS binding assays and trypsin digestion. To determine the
specificity of copper binding, ITC was used to titrate IL-1α with various metals. Some
metals like MgCl2, NiCl2, CdCl2, and FeCl2 showed weak binding, but the binding did
not induce IL-1α dimerization. This means the reaction of these metals with IL-1α were
not specific.
78

Time (min)

Time (min)
0

10

20

30

40

50

0

60

10

20

30

40

50

60

0.00
-0.50

µcal/sec

-1.50
-2.00

0.00

-3.00
0.00

0.18

kcal mol of injectant

-2.50

-0.05

-0.10

-0.15

-1

Data: uCl2102516_NDH
Model: OneSites
Chi^2/DoF = 18.13
N
0.792
±0.00577 Sites
-1
K
8.98E3 ±574 M
DH
-212.6
±2.273 cal/mol
DS
16.6 cal/mol/deg

-1

kcal mol of injectant

µcal/sec

-1.00

0.0

0.5

1.0

1.5

0.14
0.12

2.0

Data: aVSNi11816_NDH
Model: OneSites
Chi^2/DoF = 1503
N
7.55E11
±5.34E12 Sites
-1
K
1.80E10
±-- M
DH
157.7
±7.253 cal/mol
DS
47.4 cal/mol/deg

0.10
0.08
0.06

B

-0.20

A

0.16

0.0

0.5

1.0

1.5

2.0

Molar Ratio

Molar Ratio

Time (min)

Time (min)
0

10

20

30

40

50

0

60

10

20

30

40

50

60

0.00

-5.00

µcal/sec

µcal/sec

0.00

-5.00

-10.00

-10.00

-15.00

0.0

kcal mol of injectant

-1

-100.0

Data: A06182015A_NDH
Model: OneSites
Chi^2/DoF = 6.394E8
N
0.00526
±0.952 Sites
-1
K
6.79E4 ±4.91E4 M
DH
-8.561E7
±1.551E10 cal/mol
DS
-2.87E5 cal/mol/deg

-150.0
-200.0

-50.0
-100.0
Data: A130618201_NDH
Model: OneSites
Chi^2/DoF = 2.903E8
N
4.13E-5±0.0801 Sites
-1
K
1.79E5 ±1.20E5 M
DH
-1.142E9
±2.215E12 cal/mol
DS
-3.83E6 cal/mol/deg

-150.0

-1

kcal mol of injectant

0.0
-50.0

-200.0
-250.0

0.0

-250.0

0.5

1.0

1.5

2.0

Molar Ratio
0

2

4

6

8

10

Molar Ratio

D

C
Time (min)
0

10

20

30

Time (min)

40

50

60

0

10

20

30

40

50

60

1.00
0.80
0.60

µcal/sec

µcal/sec

10.00

5.00

0.40
0.20
0.00
-0.20

0.00

0.04

0.90

Data: eCl2103116_NDH
Model: OneSites
Chi^2/DoF = 178.1
N
1.09
±0.0892 Sites
-1
K
2.27E4 ±5.25E4 M
H
31.38
±4.407 cal/mol

kcal mol of injectant

Data: IL1a102616_NDH
Model: OneSites
Chi^2/DoF = 922.1
N
5.98
±11.1 Sites
-1
K
3.86
±57.2 M
DH
4646
±6.225E4 cal/mol
DS
18.3 cal/mol/deg

0.80
0.75

-1

-1

kcal mol of injectant

0.03
0.85

0.70
0.65
0.60

0.02

D
DS

0.01

20.0 cal/mol/deg

0.00
-0.01
-0.02
-0.03
-0.04

0.0

0.5

1.0

E

1.5

F

2.0

Molar Ratio

0.0

0.5

Time (min)
0

10

20

30

1.0

1.5

2.0

Molar Ratio

Time (min)

40

50

60

0

10

20

30

40

50

60

0.50

µcal/sec

µcal/sec

0.00

0.00

0.18
0.17

-1.50

-0.02

kcal mol of injectant

0.16
0.15

-0.04
-0.06
-0.08

Data: uCl2102516_NDH
Model: OneSites
Chi^2/DoF = 290.2
N
2.26
±1.03 Sites
-1
K
1.74E4 ±1.05E5 M
DH
-62.63 ±4.944 cal/mol
DS
19.2 cal/mol/deg

-1

-1

-1.00

-2.00
Data: nCl2111416_NDH
Model: OneSites
Chi^2/DoF = 20.94
N
235
±6.66E4 Sites
-1
K
0.223
±65.9 M
DH
526.8
±4423 cal/mol
DS
-1.22 cal/mol/deg

0.19

kcal mol of injectant

-0.50

0.14
0.0

0.5

1.0

1.5

2.0

-0.10
-0.12
-0.14

Molar Ratio

0.0

G

H

0.5

1.0

1.5

2.0

Molar Ratio

Time (min)
0

10

20

30

40

50

60

µcal/sec

0.00

-5.00

-1

kcal mol of injectant

-0.22
-0.23
-0.24
-0.25

Data: IL1a102616_NDH
Model: OneSites
Chi^2/DoF = 274.7
N
2.26
±0.510 Sites
-1
K
4.58E4 ±1.33E5 M
DH
-246.6 ±4.590 cal/mol
DS
20.5 cal/mol/deg

-0.26
-0.27
-0.28
0.0

I

0.5

1.0

1.5

2.0

Molar Ratio

Figure 10: Illustration of the ITC data of IL-1α titrated with different metals. A: Copper
shows strong binding affinity to IL-1α. B, C, D, E, F, G, H, and I: illustrate IL-1α has no
binding affinity to NiCl2, MgCl2, CdCl2, CoCl2, FeCl2, MnCl2, ZnCl2, and CaCl2. The
upper panels of each data represent the raw data and the bottom panels are the best fits of
the raw data. The protein concentration was made of 100 μM in 10 mM phosphate buffer
at PH 7.2. All ligands concentrations were made of 500 μM.
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In order to examine the dimerization effects of all tested metals, SDS-PAGE of interleukin
1 alpha incubated with different metals revealed that only the cupric form of copper had
the dimerization effect in interleukin 1 alpha (Figure11).

Figure 11 shows the dimerization effect of copper(II) comparing to different metals.
Monomer and dimer forms of IL-1α are S100A13 binding proteins
Studying protein-protein interactions is critical to elucidate the mechanism of IL1α export. The S100A13 protein is an important partner for signal-less proteins export by
the non-classical pathway. The unconventional secretion of FGF1 involves multiprotein
complex formation including FGF1, S100A13, and C2A of synaptotagmin 1(Syt1)29.
S100A13 is a member of the S100 proteins family which play key roles in cellular
functions with some indication of participating in tumor progression39. S100A13 is
calcium-binding protein because of the presence of the EF-hand domains40. Due to the
absence of a signal peptide, S100A13 is exported by a non-classical mechanism41. ITC
has shown that the IL-1α (monomer) is binding to S100A13 with a high affinity, so that
in this study, ITC is used to determine whether or not the copper induced IL-1α dimeric
form binds to S100A13. The data illustrates that the dimeric form of IL-1α has high
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binding affinity to S100A13 which suggests that the dimer formation is important for the
non-classical protein secretion of IL-1α. Also, the conformational change upon copper
binding that was monitored by the ANS binding assay does not alter the binding site
where S100A13 interacts.

Figure 11: A) ITC of the monomer form of IL-1α versus S100A13. B) ITC of copper
induced IL-1α dimerization versus S100A13. S100A13 shows strong binding affinity to
the dimer form of IL-1α in both conditions. The upper panels of each data represent the
raw data and the bottom panels are the best fits of the raw data. The protein concentration
was made of 100 μM versus 500 μM of S100A13 in 10 mM phosphate buffer at pH 7.2.
The type of interaction of copper induced IL-1α dimerization and S100A13 and
the monomer form of IL-1α that was titrated with S100A13 was exothermic with
negative enthalpy. The binding curve for both was hyperbolic. The binding constant (Kd)
was calculated after applying the best-fit model. The Kd value of monomer form of IL-1α
to S100A13 was 1.3 μM. Interestingly, the Kd of binding was 1.34 μM for copper
induced IL-1α dimerization.
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Copper induces several chemical shifts
Monitoring backbone conformational changes of proteins can be done using 1H-15N
heteronuclear single quantum coherence (HSQC) spectroscopy42. Studying 1H-15N
crosspeaks, the microenvironment of the amino acids can be examined upon addition of
metals or any ligand by analyzing the chemical shift perturbation43. Due to the fact that
Cu++ is paramagnetic, the resonances of the amino acid residues were beyond the
detection limit upon binding to Cu++44. Therefore, in this study, corpus chloride is used to
study the backbone conformation of the protein for two reasons. Firstly, Cu(I) is
diamagnetic, so that 1H-15N spectra are not broadened upon binding. Secondly, ITC data
showed Cu(I) binds to IL-1α, but it does not cause dimerization (Figure 12).

Figure 12: Panel A) Non reduced 15% SDS-PAGE that showed IL-1α without Cu(II)
(lane number 1), Cu(II) induced IL-1α dimerization (lane number 2), & IL-1α with Cu(I)
with no dimerization (lane number 3) Panel B) ITC of IL-1α titrated with Cu(I)
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Upon treating with copper(I), the analysis of superimposition of the 1H-15N HSQC
spectra of treated and non-treated IL-1α on the chemical shift perturbation plot showed
that copper induces drastic crosspeak shifts corresponding to where copper is binding
(Figure 13).

Figure 13: Panel-A) The 1H15N HSQC of IL-1 (red) is superimposed onto IL-1α treated
with copper (I) (blue). Panel-B) The chemical shift perturbation plot of the IL-1α treated
with copper.
In addition, residues Val2, Ile10, Lys11, Lys61, and Arg8, Ser54 that are located
in strand one undergoes drastic crosspeak shifts. Also, amino acid residues that are
located in strand two including Ala27, Ala34, and Ala35 had significant 1H-15N chemical
shift perturbation. Strand three was also perturbed as Gly96, Phe46, and Lys69 displayed
chemical shifts. Amino acids residues Asp45, Ser53, and Thr107 that are located in
strand four were also perturbed. Unfortunately, cysteine was not assigned in the data of
BMRB number 16379, so that it was not possible to calculate the chemical shift.
However, cysteine was involved in copper induced dimerization as the study showed that
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mIL-1α (C143S) was not induced to build a homodimeric form of IL-1α. 1H-15N data
analysis is consistence with the ITC data showing that IL-1α has good binding affinity to
copper as many amino acids residues are binding to copper.

Cooper induced IL-1α dimerization is less biologically active than the monomer
The level of secreted embryonic alkaline phosphatase (SEAP) produced by HEKblueTM was reduced when the cells were exposed to the media that contained copper
induced IL-1α dimerization (Figure 14). At high concentration, the dimer form shows
some activity because the media is in reduced environment that may break the disulfide
bonds producing some monomer form of IL-1α.
IL1 alpha bioactivity assay - HEK blue cells
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Figure 14: Represents the production of SAEP by HEK-blue cells upon addition of IL-1α
(0-50 ng/mL). The calculated standard errors were derived from triplicate measurements.
The monomer form of IL-1α showed significant activity as the concentrations of
SEAP increased with the concentration of IL-1α. Also, the activity of the reduced form of
copper induced IL-1α dimerization showed similar results as the monomeric form that
suggests that the breaking of disulfide bonds has no effects on the protein confirmation
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and protein bioactivity.
It is known that copper has a role in non-classical protein secretion of IL1α.
However, many questions related to the mechanism which is involved in protein export
are still unanswered. Upon binding to copper, conformational changes have occurred to
IL1α. Copper induces IL1α dimerization which increases protein stability that has been
monitored by thermal and chemical stability of the protein. Increasing the compact nature
of the protein is correlated with the results of the limited trypsin digestion which
enhances the stability of the dimer form. In the presence and absence of copper, the dimer
form of IL1α showed high binding affinity to S100A13 that suggests the involvement of
copper in non-classical secretion of IL1α is mediated by inducing the dimerization. It
looks like S100A13 is a Cu++ provider for inducing IL1α dimerization. This study should
be extended further to investigate another partner of S100A13- IL1α (monomer and/or
dimer) that helps to make the membrane to flip out and make the delivery such as in the
case of annexinII.
Conclusions
Understanding the mechanism of non-classical protein secretion of IL1α helps in
designing a treatment for several IL1α related pathological conditions such as cancer and
rheumatoid arthritis. We were able to successfully demonstrate the copper induced
dimerization of IL1α under in vitro conditions. At approximately 46 µM of CuCl2, the
monomeric form of IL1α transforms into a dimer. We have identified the Cu2+ mediated
mechanism of dimerization where the single cysteine at position 143 becomes oxidized
resulting in the formation of an inter-disulfide bond leading to the generation of the
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homodimer. Also, the result that was gained from this study found that the dimer form of
IL1α has binding affinity to S100A13 as well as the monomeric form.
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Chapter Four
Investigation the Role of Amlexanox in Non-Classical Secretion of Interleukin 1
alpha
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Abstract
The interleukin-1 (IL-1) family of pro-inflammatory cytokines is known to amplify
cancer metastasis, making them potential targets for treatment. Non-classical secretion of
IL-1α appears to be mediated by a Cu2+ binding. Hence, development of drugs to inhibit
the Cu2+ mediated oligomerization and resultant multiprotein complex interactions could
block tumor angiogenesis. This study focused on elucidating the underlying molecular
effects of non-classical release of IL-1α upon treatment with the drug amlexanox (AMX).
AMX has low solubility below pH 8.2. This finding is characteristic of metal chelators
such as ethylenediamine tetraacetic acid (EDTA), nitrilotriacetic acid (NTA), and
iminodiacetic acid. Also, AMX can bind to copper as well as IL-1α that may interfere with
the non-classical secretion of the protein. Binding of IL-1α to AMX may induce
conformational changes, which interfere with the flexibility and stability of IL-1α. This
study shed light in identifying the cause and plausible mechanism involved in the secretion
of these intriguing cytokines, which could pave the way towards development of potent
cancer drugs.
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Introduction
IL-1α is a key member of the IL-1 family1, 2. It is unique in certain properties
compared to the other members of the cytokine family3, 4. IL-1α expression is
significantly responsive to wide range of external stimuli5-7. IL-1α plays a key role in
many cellular processes such as inflammation, proliferation, and immunological reactions
against many microbial infections8, 9. IL-1α also plays key roles in molecular decisions
during infections and stress conditions10, 11. Cellular reposes to IL-1α actions represents
through the inflammatory mechanism that activates inflammatory cells 12, 13. Also, many
studies have linked IL-1α to wound healing, rheumatoid arthritis, cancer metastasis, and
Alzheimer’s disease12, 14. IL-1α lacks the signal segment that guides protein secretion
through the endoplasmic reticulum-Golgi apparatus complex15, 16. In non-classical
secretion of IL-1α, multiprotein complex formation takes place that acts as a cargo
targeting IL-1α to be exported outside the cells15, 17. The underlying mechanisms
governing IL-1α export from cells requires further investigation. Also, the mechanism of
multiprotein complex formation of IL-1α and S100A13 inside cells needs to be
deciphered. S100A13 is a member of S100 protein family that binds to calcium18, 19. The
S100 protein family is characterized by forming two EF segments that are classified into
a C-terminal hand and an N-terminal hand20-22. S100A13, a Ca2+ binding protein, is a
small protein that exhibits ubiquitously in different tissues such as intestine, heart,
kidney, ovary, and muscles23-25. S100A13 regulates a wide range of cellular functions
including cellular proliferation, muscle contraction, and protein export26-28. In fact,
S100A13 is the only S100 member that is involved in protein translocation of signal-less
proteins by non-classical protein secretion during cellular stress29-31. IL-1α is well known
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as an angiogenic cytokine that secretes into the extracellular compartment under stress
conditions without a signal peptide32, 33. Uncontrolled release of IL-1α is responsible for
various pathological conditions such as autoimmune disorders and tumor angiogenesis 8,
34.

Several reports confirmed the role of IL-1α in the growth progress of breast and

intestinal cancer9, 35. Several studies have shown copper (Cu2+) is involved in nonclassical secretion of signal-less proteins36-38. Cu2+ plays a crucial role in forming
multiprotein complex release of FGF139, 40. It was demonstrated that amlexanox (AMX)
(Figure 1), the anti-allergic and anti-inflammatory drug41, can inhibit non-classical
secretion of FGF142. The mechanism that involves the inhibition of FGF1 secretion by
AMX includes different processes. Some scientists confirmed that AMX binds to
S100A13, which in return prevents multiprotein complex formation that includes FGF1
and S100A1343, 44. Also, some studies showed that AMX is used to treat aphthous ulcers,
inflammation of gums or tongue, because it inhibits the release of inflammatory
mediators45, 46. Studying the role of AMX in exporting IL-1α paves the way for
developing a new drug that inhibits the non-classical secretion of IL-1α.

Figure 1: depicts the chemical structure of amlexanox47.
The main objective of the present study is to shed light on how AMX binds to
IL-1α and stops non-classical secretion of the protein. This investigation includes several
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physical experiments to elucidate the role of AMX on the monomer/dimer form of IL-1α
and to investigate if AMX may be involved in regulating copper involvement.
Materials and Methods
Materials All buffer components including Na2HPO4, NaH2PO4, and NaCl were
purchased from VWR Scientific Inc, USA. Lysogeny broth (LB) and urea were bought
from EMD Millipore, USA. 1-anilino-8-naphthalene sulfonate and Trypsin were obtained
from Sigma. Nickel sepharose was obtained from GE Healthcare, USA.
Far-UV Circular Dichroism Spectroscopy Far-UV CD measurements were
accomplished using Jasco 1500 spectrometer to determine the secondary structure
changes. To obtain the CD spectrum, the machine was setup to scan the protein samples
at a speed of 20 nm/min using wavelength of 190-250 nm at 25°C or at specific
temperature when it was required. The protein concentration of 0.5 mg/mL in 10mM
phosphate buffer (pH 7.2) was examined. All data were smoothed using the SavitzkyGolay algorithm for the best fit. Far-CD was used for studying the following experiments
A: Thermal Denaturation Thermal denaturation studies were performed on the JASCO1500 spectrometer to reveal how temperature affects the stability of IL-1 in presence and
absence of AMX. Spectra were collected from 25°C to 90°C in five-degree intervals.
B: Chemical Denaturation (Urea denaturation) For the chemical denaturation studies,
8M urea was used to induce protein denaturation. This process was monitored using
JASCO-1500 s spectrometer. Data of samples of 0.5 mg/ml proteins in 10 mM PB were
each over the titration of urea. Samples of 0.5 mg/ml protein in 10 mM PB were used for
titration with urea. These experiments revealed information about the stability of the
protein in the presence and absence of AMX.
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Extrinsic Fluorescence experiment Extrinsic fluorescence experiments (ANS binding
assays) were performed using a Hitachi F-2500 fluorescence spectrophotometer at 25°C
to provide information regarding the protein’s tertiary structure. ANS (8anilinonaphthalene-1-sulfonic acid) is an extrinsic fluorophore that fluoresces when it
binds to solvent exposed hydrophobic regions of a protein. A protein concentration of 0.5
mg/mL in 10 mM phosphate buffer, pH 7.2 was used. All fluorescence measurements
were recorded using the slit width set to 2.5 nm, excitation wavelength of 280 nm, and
emission wavelength range from 300-450 nm. Performing ANS binding assays, the
titrations were carried out by adding 1μL of ANS per interval. The relative fluorescence
intensity was recorded at 510 nm.
Limited Trypsin Digestion (LTD) Proteolytic trypsin digestion was performed to
determine the structural flexibility of the protein with and without the ligand. Trypsin
cleaves peptide bonds at the C-terminal end of lysine and arginine amino acids residues.
The water bath was used to incubate the samples immediately at 37 °C. After the samples
were removed from the water bath, TCA preparation was performed on each sample to
stop the trypsin reaction. Samples were then assessed using 15% SDS-PAGE analyzed
with UN-SCAN-IT gel software (Silk Scientific Inc., USA). The intensity of the bands in
the gel stained with Coomassie blue were compared to control bands containing pure
protein with or without the ligand.
Isothermal titration calorimetry (ITC) Isothermal calorimetry (ITC) is a great
thermodynamic technique used to study the binding affinity of interacting
macromolecules, by measuring changes in entropy and enthalpy in this case, the binding
of AMX and IL-1α. The ITC system consists of two adjacent cells (reference cell and
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sample cell) in an adiabatic jacket, which prevents heat transfer between the environment
and the cells. Protein samples were prepared in 10 mM phosphate buffer pH 7.2. The
protein sample was degassed at 25⁰C before titration. During the titration, the generated
heat from the binding of ligands to the protein was measured. Then, the data was
processed using Origin software provided by the manufacturer to get the best fit. Kd
value, the equilibrium dissociation constant of the reaction, was calculated for each
ligand.
Results and Discussion
AMX behaves as copper chelator molecules
Amlexanox needs high pH to be dissolved completely. It dissolves at pH 8.8, 10
mM phosphate buffer. Dissolving at high pH is characteristics for metals chelators such
as EDTA48. This finding may suggest that AMX can be used as copper chelators. In this
context, ITC was performed to confirm whether or not AMX binds to copper (Figure 2).
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Figure 2: Isothermogram representing the binding of AMX to copper. The data
represented the best curve fit using ITC software.
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The calculated Kd value calculated from the ITC data was 1.6 µM. This finding
indicates that AMX can regulate the involvements of copper in many biological
processes.
AMX prevents copper induced IL-1α dimerization
The previous results may indicate that AMX could stop copper induced IL-1α
dimerization. The homodimer of IL-1α is mediated by the oxidation of the thiol group of
cysteine 143. In order to examine this theory, IL-1α was incubated with different
concentrations of AMX followed by addition of 46 µM of CuCl2, the concentration
required to induce dimerization to 100 µM of IL-1α completely. 15% SDS-PAGE was
used to reveal the results (Figure 3 A & B). It seems that AMX prevents oxidation of
Cys143’s thiol group by copper, so that inter-disulfide bond formation was blocked.
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Figure 3: A) AMX interferes with Cu++ induced IL-1α dimerization. The protein
samples were first incubated with different concentrations of AMX and then CuCl2
was added. The numbers above the gels represent the protein samples based on
AMX concentrations: 1) IL-1α monomer, 2) 20μM AMX, 3) 25μM AMX, 4) 30μM
AMX, 5) 35μM AMX, 6) 40μM AMX, 7) 45μM AMX. 8) 50μM AMX, 9) 55μM
AMX, 10) 60μM AMX, 11) 65μM AMX, 12) 70μM AMX, 13) 75μM AMX, 14)
80μM AMX, 15) 85μM AMX. 16) 90μM AMX. 17) 100μM AMX. B)
Densitometric scan of the monomer formation of IL-1α that induce at different
concentrations of AMX.
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AMX binds to IL-1α
ITC was used to determine AMX binding affinity of IL-1α. The binding affinity is
represented by the dissociation constant (Kd) value that is the reciprocal of the
association constant (Ka) value. Ka value is obtained from ITC data. A small Kd value
correlates to high binding affinity. The Kd value for AMX binding to IL-1α was 1.9 µM
as shown (Figure 4). This indicates AMX has high binding affinity to the protein. These
results may confirm that AMX might be used for inhibiting non-classical release of IL1α.
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Figure 4: Isothermogram representing the binding of AMX to IL-1α. Protein
concentration was 100 µM and AMX was 50 µM. All samples were prepared in
phosphate buffer.
AMX decreases IL-1α affinity to copper
Copper induced IL-1α dimerization is mediated by cysteine 143. Copper oxidizes
the thiol group to convert cysteine to cystine. Forming a disulfide bridge between two
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protein molecules. AMX prevents IL-1α dimerization by copper and also it chelates
copper. AMX prevents copper-induced IL-1α dimerization by chelating copper. In order
to confirm that AMX and copper bind in the same site, ITC was performed with IL-1α
mixed first with AMX then titrated with copper chloride (Figure 5). ITC data showed that
copper lost its affinity to IL-1α in presence of AMX.
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Figure 5: ITC data is showing the binding of copper to AMX bound IL-1α. After AMX
binding, the bound form was dialyzed to remove all AMX that can bind to copper. All
samples were prepared in phosphate buffer.

AMX binding alters IL-1α conformation
Anilino naphthalene 8-sulfonate (ANS) is a non-polar reagent used to examine the
flexibility of solvent-exposed hydrophobic surfaces in proteins. Upon binding to
hydrophobic pocket within the protein, ANS fluoresces which helps examine the
structural rigidity of proteins. Hydrophobic interactions of proteins are important in
protein folding and stability. Upon binding to ANS, IL-1α shows an emission maximum
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at 510 nm and the surface exposed hydrophobic regions of protein in presence of AMX
were saturated at ANS concentration of 150 µM (Figure 6). Whereas the ANS saturation
curves of IL-1α without AMX were saturated at ANS concentration 115 µM. These
finding suggest that in presence of AMX, the protein is more structurally flexible in
which the solvent exposed hydrophobic surfaces are reduced in presence of AMX,
indicating that AMX helps shift the protein to a more compact state.
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Figure 6: ANS binding curve of IL-1α with and without AMX.
AMX increase IL-1α flexibility
Limited proteolytic digestion experiment investigates the mode of action between
the protein and the ligand. In general, protein-ligand binding can mask the potential
cleavage sites of the substrate. The masking will delay the proteolytic enzyme to reach
the cleavage sites. This delay can be detected by analyzing the differences in the cleavage
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pattern between the free protein and the protein-ligand bound forms on the SDS-PAGE
gel. In order to study the effects of AMX on the conformational flexibility of IL-1α,
limited trypsin digestion was used. Trypsin cleaves at the carboxyl end of the amino acids
lysine and arginine unless proline comes after either one of them. IL-1α has four arginine
residues and eleven lysine residues and both are not followed by proline, so there are
fifteen potential trypsin cleavage sites. In time dependent trypsin digestion, protein
samples were incubated at 37 °C using water bath. Then, the results were revealed using
15% SDS-PAGE gel followed by measuring the bands intensity using densitometric scan.
With no AMX, IL-1α was more susceptible to trypsin in which trypsin cleaved 50% of
the proteins after 25 minutes whereas IL-1α in presence of AMX got cleaved after 35
minutes (Figure 7). It seems that binding to AMX, IL-1α has enhanced resistance to
trypsin action. This indicates that AMX binds where trypsin cleavage sites are located.
This decreased susceptibility to trypsin digestion suggests that the backbone of IL-1α
mixed with AMX is more flexible than IL-1α alone.
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Figure 7: Densitometric plot of limited time trypsin digestion showing the rate of
cleavage of IL-1α, incubated at 37⁰C. The insert shows the 15% SDS-PAGE with
lanes 1-9 representing 5, 10, 15, 20, 25, 30, 35, 40, and 45 minutes.
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IL-1α is stabilized by AMX
Thermal denaturation of IL-1α was examined by circular dichroism from 25-90°C at 5°C
increments. Unfolding of the proteins under different temperatures was monitored by the
change in secondary structure of IL-1α at 208 nm and 215 nm. The temperature-induced
unfolding curves of the IL-1α with no AMX and IL-1α with AMX show that IL-1α with
AMX is more stable at higher temperatures than the protein alone, shown in (Figure 8).
Denaturation midpoint (Tm) where 50% of the proteins are in the folded state was 65 °C
in presence of AMX whereas with no AMX the Tm was 60°C. These results indicate that
AMX has good affinity to IL-1α.
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Figure 8: Thermal denaturation of IL-1α in presence of AMX (purple squares) and
absence of AMX (red rhomboids). Far-CD was probed to examine of the protein at
different temperature from 25-90°C within 5°C increments.
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The chemical stability of IL-1α without and with AMX was examined by urea-induced
protein unfolding experiment using Far-CD spectroscopy (Figure 9).
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Figure 9: Chemical denaturation of IL-1α in presence and absence of AMX. Far-CD was
probed to examine of the protein stability in urea.
In presence and absence of AMX, the protein exists in the native conformation at
zero concentration of urea. During titration with urea, the unfolded states of the protein
molecules are monitored. The Cm values where 50% of the proteins exist in folded state
were calculated from urea unfolding curve. The Cm value of IL-1α with AMX was 4.3 M
urea whereas without AMX the Cm a value was 3.3 M urea. The results indicated that as
urea is neutral denaturant that disturbs hydrogen bonds within the protein molecules, so
in presence of AMX, urea interfered with the hydrogen binds occurred at high
concentration. As urea is a neutral denaturant that disturbs hydrogen bonds within protein
molecules, these results indicate that in the presence of AMX urea interferes with the
hydrogen bonds at high concentrations. These results of protein stability are consistent
with the findings of limited trypsin digestion and ANS binding assay that showed
conformational changes may increase protein compact structure.
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Conclusions
The non-classical secretion of signal-less protein involves protein cargo that is
made from multiprotein complex. The non-classical secretion of signal-less proteins
involves a multiprotein complex for transport. In the case of IL-1α, S100A13 is involved
in protein export in presence of copper. The results of this study showed that AMX can
bind to IL-1α and also chelates copper. AMX binds to cysteine 143 of IL-1α where
copper can bind and form a homodimer of IL-1α. Therefore, AMX can mask the thiol
group and protect it from copper oxidation. Upon binding to AMX, IL-1α showed some
conformational changes that stabilized the protein in some ways. For future work, NMR
would be beneficial for examining other amino acid residues in the AMX binding site of
IL-1α. In vivo study could help to determine whether or not AMX can inhibit nonclassical secretion of IL-1α by binding to it, by chelating copper, or both.
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Chapter Five
Conclusions
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Conclusions
Technologies that involve recombinant DNA producing recombinant proteins
have drastically changed the world’s pharmaceutical market. Protein drug research
development has allowed for the potential treatment of other ailments such as autoimmune diseases, cancer, hypertension, mental disorders, metabolic diseases, as well as
cardiovascular disease. Many therapeutic proteins have been successfully produced by
recombinant DNA technology. The overproduction and purification of recombinant
proteins is a multibillion-dollar business. Significant advantages of recombinant protein
drug therapy make the production efforts not only worthwhile, but also extremely
important. When recombinant protein expressed as inclusion bodies in E. coli cells,
multiple steps require to obtain soluble and biologically active target protein. As multiple
steps leading to lower yield of pure protein that could hindered the study of many
proteins and driven up the cost of many pharmaceuticals. Therefore, there is great interest
to pharmaceutical and biotechnology industries to develop an efficient strategy for
purification of recombinant proteins. In this context, several affinity tags have been
successfully proposed for the purification of recombinant proteins. However, the
currently commercially available affinity tags have some difficulties for example
requirement of exhaustive purification conditions, high costs of the solutes used for
fraction elution, protein tags are prone to denature at high conditions, weak solubility
enhancer, target proteins are not recovered as a fully bioactive form, and limited
pharmaceutical/biotechnology applications. This study pertains to the successful
development of a novel solubility affinity tag which can be used for the simple, versatile,
and cost-effective purification and detection of recombinant proteins expressed as
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inclusion bodies. In addition, the affinity tag has wide range applications in
pharmaceutical and biotechnological field. The novel Ark-RUBY-tag facilitates rapid,
reproducible and single-step purification of recombinant proteins expressed as inclusion
bodies in E. coli cells as it is shown in purifying IL-1 alpha and D2 domain. Purification
of ArK-RUBY-fused recombinant protein(s) can be obtained by using imidazole
fractions. Target protein can be easily removed from the Rd-tag by enzymatic cleavage.
No requirement for desalting step in order to get purified, target protein. Rd-fused
recombinant proteins can be quantitatively detected using polyclonal antibodies. Rd-tag
can be used to purify small peptides. By using Ark-RUBY-tag, purified recombinant
protein regains fully biologically active form. Therefore, bioactive protein has wide range
of application in drug-delivery.
The non-classical secretion of signal peptide-less proteins is still unclear and
under research. While some proteins have displayed good binding affinities to S100A13,
the protein involves in non-classical secretion, some critical steps are still ambiguous. For
example, the mechanism of multi protein complex formation that involves in interleukin1 alpha is still unwell understood. Also, there is no suitable answer for how copper
chelator prevents IL-1 alpha secretion. In this study, in order to understand plausible
mechanism underlying the role of copper in non-classical secretion of IL-1 alpha, an
investigation was made to study the effects of copper and different metals on IL-1 alpha.
Copper involves in many crucial biological reactions in the cells. Even though copper ion
is toxic when it is free, the mechanism(s) underlies intracellular copper transportation is
still unknown. It is known that copper involves in non-classical secretion of many signal
peptide-less proteins. The IL-1α is shown to bind to Cu++ with apparent binding constant
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value in nanomolar range. It seems that Cu++ induces protein conformational changes
leading to protein dimerization which we believe the dimerization event play a crucial
role in protein secretion by non-conventional mechanism. Also, we believe that S100A13
is Cu++ donor since S100A13 is copper binding protein. In this study IL-1α was also
tested to interact with several metals in order to examine whether or not copper is specific
for dimerization. The results are shown that cupric form of copper is the only metals that
underlies protein dimerization, whereas cuprous form copper shows good binding with no
conformational changes. Copper induced IL-1α dimerization was inhibited when
reducing agents is added, so that an attempt is made to design mutation on Cys134
position since IL-1α has only one cysteine. The results of this study reveal that the
dimerization is mediated by disulfide bridge of two cystine. Both monomer and dimer
form show good binding affinity to S100A13 which suggests that S100A13 binding site
to IL-1α has no conformational changes.
In previous study on FGF-1, Amelexanox (AMX), the drug that is used for
reducing inflammatory reaction, was able to inhibit FGF-1 secretion. The results of this
study showed that AMX binds to IL-1α in constant affinity in the micromolar range.
AMX induces protein conformational changes around Cys134 because it prevents protein
dimerization. Also, AMX shows a good binding to copper which we believe that AMX
works as copper chelator reagent or it binds to Cys134 and prevents copper to reduce
Cys134. Another event may occur in dimerization prevention mechanism which is AMX
converts corpus to cupric which in return it prevents dimerization. The results of AMX
are promising to design a drug that may help in inhibiting IL-1α secretion that is
associated with many diseases.
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